Search this site

Nelson Advisors: Switzerland's MedTech Paradox: Record Growth, Fading Appeal Switzerland's medical technology industry is having a strange kind of year. By almost every headline measure, it is thriving: output is expanding at twice the rate of the broader Swiss economy, exports are climbing, and research spending remains among the highest of any industrial sector in the country. Yet beneath those numbers, the people who run the country's medtech companies are sounding an alarm that has been building for several years and has now become impossible to ignore. According to Swiss Medtech's 2026 sector study, the trade association representing the country's medical technology companies, Switzerland's long standing appeal as a place to invest, manufacture, and innovate in medtech is eroding, quietly, but unmistakably. It is a paradox worth taking seriously, not just for the roughly 1,400 companies and 72,000 employees who make up the sector, but for a country whose economic identity has long rested on precision manufacturing, life sciences and a reputation for stability that global companies have historically been willing to pay a premium to access. If that premium is starting to look less worthwhile, the implications reach well beyond one industry. A sector still outperforming the economy around it Start with the good news, because there is real good news. Swiss medtech has grown at an average annual rate of 5.5% over the past two years, roughly double the growth rate of the Swiss economy as a whole. The sector now accounts for close to 10% of Switzerland's industrial value added, exports around CHF 12 billion worth of goods annually, and generates a trade surplus of roughly CHF 5.5 billion, making it the third-largest contributor to the country's trade balance behind pharmaceuticals and watchmaking. Medtech companies reinvest around 12% of turnover into research and development, a ratio that puts the sector among the most research-intensive in the Swiss economy, comparable to segments of pharma and precision engineering. There is also a quieter efficiency story hiding in the numbers. Swiss medtech products account for about 7.9% of the country's total medical expenditure, yet the cost of those products has risen only 1.9% in recent years, well below the 3.3% increase seen across healthcare spending more broadly. In an era when healthcare cost inflation is a political flashpoint in almost every developed country, that is not a small thing, it is evidence that the sector is delivering more clinical value per franc spent, not less. By any conventional measure of industrial health, this looks like a sector firing on all cylinders. So why is Swiss Medtech, the industry's own trade body, using its flagship annual study to warn that the country is losing its edge? The numbers hiding underneath the headline growth The answer lies in a set of figures that sit uncomfortably next to the growth story. The first is jobs. Over the past decade, the Swiss medtech sector has typically added around 1,500 net new jobs a year, a steady, dependable engine of skilled employment in cantons from Bern to Zug. Over the past two years, that number has collapsed to just 200 net new jobs in total. Not 200 a year, 200 across the entire two-year period. A sector growing at 5.5% annually and adding almost no new employment is a sector that is either becoming dramatically more productive, moving its hiring elsewhere, or both. Swiss Medtech's data suggests it is largely the latter: companies are still growing revenue, but they are increasingly choosing to do the growing outside Switzerland. The second warning sign is investment intent. In the latest survey, 43% of companies said they have no plans for new investment in Switzerland, the highest share since Swiss Medtech began tracking the question. That is not a marginal shift in sentiment; it is closer to half the industry effectively pausing on domestic capital deployment at a moment when the sector's own growth would, in an earlier era, have been expected to fuel expansion of factories, labs, and headcount at home. The third is funding for the activities that have historically defined the sector's competitive advantage: production and R&D. Swiss Medtech's study points to a clear and continuing decline in the capital allocated to both. For an industry whose entire value proposition rests on precision manufacturing and research intensity, a pullback in exactly those two areas is arguably the most concerning signal of all, more so than any single quarter's growth or export number. Layered on top of these figures is a broader sentiment shift. More than half of surveyed companies now rate Switzerland's attractiveness as a business location less favourably than they did five years ago. That is a remarkable reversal for a country that has spent decades positioning itself, successfully, as one of the most desirable places in the world to locate high value medtech operations, thanks to its regulatory credibility, skilled workforce, and proximity to both European and global markets. Damian Müller, a member of Switzerland's Council of States and president of Swiss Medtech, framed the stakes plainly around the release of the study: the question the industry now faces is not whether medtech innovation has a future, but whether that future will still be located in Switzerland. Simon Michel, CEO of Ypsomed, one of the country's best-known medtech manufacturers, put it even more bluntly, noting that competing locations in the EU, China, and the United States have simply become more attractive than Switzerland for new investment decisions. When the CEO of a flagship national champion says that out loud, it tends to get noticed in Bern. What is driving companies away, or at least giving them pause It would be easy to assume a slowdown in a globally exposed, R&D intensive sector is simply about currency strength, interest rates, or the general chill that has settled over medtech and life sciences investment worldwide since 2022. Those macro pressures are real and Swiss Medtech does not pretend otherwise. But the study is notably specific about what companies themselves point to as the deciding factor: cost pressure combined with bureaucratic hurdles, rather than any loss of Swiss technical expertise or manufacturing quality. That distinction matters. Switzerland is not losing companies because its engineers, regulatory scientists, or production quality have gotten worse, by most accounts they remain excellent. It is losing relative ground because the cost and complexity of doing business domestically have risen faster than the value companies get in return, at exactly the moment competitors have made themselves easier to work with. Tellingly, the study notes that traditional Swiss medtech expertise, long the trump card in investment decisions, has not been the top-ranked investment criterion for companies since 2018. Cost and regulatory ease have overtaken it. Nowhere is that regulatory friction more visible than in the tangled, half-decade saga of Switzerland's market access relationship with the European Union, which takes in roughly half of all Swiss medtech exports. The regulatory backdrop: five years of friction with the EU To understand why "bureaucracy" is not an abstract complaint but a specific, quantifiable cost for Swiss medtech companies, it helps to look at what happened to the Mutual Recognition Agreement (MRA) between Switzerland and the EU for medical devices. The MRA effectively allowed Swiss certified devices to be treated as compliant in the EU market and vice versa. It lapsed in May 2021 after broader Swiss-EU institutional negotiations broke down, and Switzerland was overnight reclassified as a "third country" for medical device purposes. The practical consequences were immediate and expensive: Swiss manufacturers lost the ability to have their CE certifications recognised through Swiss notified bodies, were required to appoint a dedicated Authorised Representative inside the EU, had to register separately in the EU's EUDAMED database, and lost the vigilance and market-surveillance efficiencies that database access provides. For a sector that sends nearly half its output to the EU, this was not a paperwork inconvenience, it was a structural tax on every product launch and every regulatory update. There has been real diplomatic movement to fix this. Following a broader Swiss-EU trade framework agreed in late 2024 and roughly two years of negotiation, an updated MRA was signed in March 2026, including a "dynamic alignment" mechanism designed to keep Swiss and EU device regulation automatically in step going forward, preventing a repeat of the 2021 rupture. That is genuinely good news, and it is the kind of outcome Swiss Medtech has been pushing for. However, and this is the detail that matters for any company making an investment decision in 2026, the agreement is signed, not yet ratified. It still requires approval from the European Parliament and Council, and very likely a domestic referendum in Switzerland given how Swiss-EU treaties are typically handled. Realistic estimates put full implementation no earlier than late 2027. Until then, every one of the barriers introduced in 2021 remains in force: dual registration, EU representation requirements, and exclusion from EUDAMED all continue to add cost and delay for Swiss exporters, even as the political headlines suggest the problem has been "solved." That gap between political resolution and operational reality is precisely the kind of unnecessary bureaucracy Swiss Medtech's leadership is calling out. It is also why the industry, in parallel, has been lobbying alongside its European counterpart, MedTech Europe, for a substantive revision of the EU's own Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR), rules widely criticised across the European medtech industry, not just in Switzerland, for imposing compliance costs that fall disproportionately on smaller manufacturers and slow the introduction of incremental device improvements that pose little safety risk. Swiss authorities have simultaneously pursued a parallel-track strategy of seeking formal recognition of FDA-approved devices, partly as a hedge against continued MDR/IVDR complexity and partly as leverage to encourage the EU itself to accelerate reform. Seen against this backdrop, the 43% of Swiss medtech companies pausing investment and the collapse in job creation look less like a mysterious loss of confidence and more like a rational response to several years of regulatory limbo layered on top of already-high Swiss operating costs. Where the growth is actually coming from None of this means Swiss medtech has lost its capacity to innovate, quite the opposite. The sector study identifies artificial intelligence and digitisation as the areas of greatest growth potential going forward, alongside a broader industry shift toward integrated, patient centred solutions that combine devices, software, and data rather than selling standalone hardware. This is consistent with where global medtech investment has been heading for several years, and Swiss companies are not being left behind on the technology roadmap itself. The catch is talent. Switzerland's study points to a shortage of AI and digital skills sufficient to meet this new direction of travel, and tellingly some companies are responding not by training locally but by building digital and AI teams abroad, in markets where that talent is more readily available. This is a subtler version of the same story playing out in jobs and investment more broadly: the work is still happening, the growth is still real, but an increasing share of it is happening somewhere other than Switzerland. What Swiss Medtech is asking for Given this diagnosis, Swiss Medtech's policy prescription is narrower and more targeted than a generic call for "more competitiveness." The association is explicitly asking the Swiss government and regulators for: Systematic reduction of unnecessary domestic bureaucracy and administrative burden on medtech companies, rather than incremental or piecemeal fixes Removal of trade barriers through ratification and implementation of international agreements, above all the updated EU MRA, so Swiss companies stop paying the ongoing cost of an already-agreed political fix that has not yet taken legal effect Investment in digital and AI skills infrastructure domestically, so that the sector's own stated growth opportunity does not simply migrate to wherever the talent already exists Continued advocacy, alongside European partners, for a more proportionate MDR/IVDR framework that does not penalise smaller and mid sized manufacturers disproportionately relative to the safety benefit gained None of these asks are radical. They amount to a request that Switzerland stop making its own historic strengths, regulatory credibility, technical depth and a stable business environment, harder to access than they need to be. Swiss Medtech's framing is notably not defensive; it does not ask for protection from competition, subsidy, or special treatment. It asks, in effect, for the country to get out of its own way. A sector of small companies, not just Ypsomed sized giants It is worth remembering what the Swiss medtech landscape actually looks like beneath the handful of internationally recognisable names. The overwhelming majority of the sector's roughly 1,400 companies are small and medium-sized enterprises, many clustered in specialist regions such as the Bern-Solothurn-Jura "Medtech Alley," the Lake Geneva life sciences corridor around Vaud and Geneva, and the precision-manufacturing hubs of Ticino and central Switzerland. These firms rarely have in-house regulatory affairs departments the size of a large multinational's, nor the balance sheet flexibility to simply absorb a few years of dual EU-Switzerland registration costs while waiting for a treaty to be ratified. That distinction helps explain why the aggregate growth figures and the aggregate warning signs can both be true at once. A relatively small number of larger, globally diversified manufacturers can continue growing revenue by leaning on capacity and regulatory infrastructure they have already built outside Switzerland, while a much larger number of smaller, domestically rooted suppliers, the companies that historically provided the bulk of the sector's steady job creation, are the ones most likely to freeze hiring, delay a planned facility upgrade, or quietly shift a product launch to an EU-based contract manufacturer instead. If that pattern continues, Switzerland risks hollowing out the very tier of the industry that gives it depth and resilience, even while headline export and turnover figures stay healthy for another few years. Why this matters beyond one industry It is tempting to read a sector study like this as a niche concern for an industry most people only think about when they need a hip implant or a glucose monitor. That would understate the significance. Medtech is Switzerland's third-largest trade surplus contributor, sits alongside pharma and finance as a pillar of the country's high-value export economy, and offers exactly the kind of skilled, well-paid, R&D-adjacent employment that most advanced economies are competing hard to attract and retain. A sector that can grow revenue at 5.5% a year while adding almost no net jobs and pulling back on capital investment is not a sector in crisis today, but it is a sector quietly relocating its future growth elsewhere, one investment decision at a time. The MRA saga is instructive precisely because it shows how much of this erosion is self-inflicted or at least addressable through policy, rather than being an unavoidable consequence of global competition. A five year gap in mutual recognition, a signed but unratified fix, and a further eighteen month plus wait for implementation together represent roughly a lost half-decade during which Swiss exporters absorbed costs their competitors did not have to bear. That is not the kind of disadvantage that clever engineering or research intensity can fully offset. Switzerland retains genuine, durable advantages in medtech: deep technical expertise, a dense cluster of suppliers and specialists, proximity to both European and global markets, and a regulatory reputation built over decades. The 2026 sector study is best read not as a story of decline, but as a warning that those advantages are not self-sustaining. They have to be actively defended against a steady accumulation of avoidable friction, friction that competitor jurisdictions in the EU, the US, and increasingly China have been working systematically to reduce. Whether Switzerland treats this as an urgent policy priority, or as background noise beneath an otherwise reassuring growth headline, may determine which country captures the next decade of medtech investment that Swiss companies themselves are generating. Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns.www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA#Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk

Nelson Advisors: NHS Health IT Market Forecast to Hit £8.3 Billion by 2030 as Productivity Pressures Mount The NHS IT market is entering one of its most consequential growth phases in years. New analysis from Future Health Intelligence (FHI) forecasts that spending on NHS technology will climb from £6.1bn today to £8.3bn by 2030, adding more than £2bn in new market value over the next four years and cementing digital health as one of the fastest-growing corners of the UK public sector IT landscape. For an industry that has weathered its share of false starts and stop-go funding cycles, this is a striking signal: the direction of travel is not just upward, it's accelerating. The forecast was unveiled during an FHI webinar on 11th September, drawing on the FHI Market Model, a proprietary framework that tracks current and projected health IT spend across five categories. It's a number worth sitting with. An annual growth rate of 6.1% between 2025 and 2030 would outpace general public sector IT spending growth in most comparable forecasts, and it arrives at a moment when the NHS is under sustained pressure to do more with less. That combination, rising technology investment inside a service otherwise being asked to hold costs flat, is exactly the tension that makes this market interesting to suppliers, investors, and NHS leaders alike. Why the Money Keeps Flowing The politics around NHS funding are, as ever, unsettled. Tola Sargeant, associate director at FHI, addressed this directly in comments to Digital Health News, noting that there is real uncertainty over how government spending priorities might shift under Andy Burnham as prime minister. It's a fair note of caution. Changes in political leadership have, historically, come with changes in departmental priorities, spending review timetables, and appetite for large-scale technology programmes. Anyone who lived through the shifting fortunes of the National Programme for IT, or the various restructurings of NHS Digital and NHSX, knows that NHS technology strategy rarely survives a change of government untouched. And yet Sargeant's core message was one of confidence rather than caution: "NHS investment in digital, data and tech is set to remain significant and growing over the next five years as the government strives to improve NHS productivity and the quality of services without increasing costs." That's the crux of it. Digital investment in the NHS has increasingly become decoupled from the question of whether a given government is "pro-tech" or not, and recoupled instead to a much harder, more structural problem: the NHS cannot meaningfully improve productivity through headcount growth alone, and the political room to simply spend more on frontline services without offsetting efficiency gains has narrowed considerably. Technology is one of the few levers left that can plausibly deliver more care without proportionally more money, more staff, or more beds. Sargeant's second point is arguably even more significant for anyone selling into or investing in this market: "Against a backdrop of reorganisation and workforce changes, external support will be key to delivering this step-change, creating opportunities for IT suppliers." NHS organisations undergoing structural change, trust mergers, integrated care board reconfigurations, workforce reductions in corporate and back-office functions, typically lose exactly the kind of in-house digital capability and organisational memory needed to run large technology programmes well. That capability gap doesn't close the funding tap; if anything, it widens the addressable market for external suppliers, consultancies, and managed service providers who can plug the gap. Reorganisation, in other words, tends to be good for supplier revenue even when it's disruptive for NHS IT teams themselves. Where the Growth Is Concentrated The FHI Market Model breaks local NHS IT spending into five categories: software, IT services, networking and communications, hardware, and other spending (which includes ICT staff costs). Of these, software is comfortably the largest, accounting for 35% of total local NHS IT spending in 2025/26. FHI's analysis predicts that share will grow further still, to 37% by 2030/3, a notable finding given how mature the electronic patient record (EPR) market already is in England. Most acute trusts have now either completed or are well into major EPR replacement or upgrade programmes, which might reasonably be expected to plateau software spend as a proportion of the whole. That FHI instead sees software's share continuing to rise suggests the next wave of growth isn't really about EPRs at all, it's about what gets built and bought around and on top of them. That next wave has a fairly clear shape. FHI singles out AI led software, with ambient voice technology (AVT) called out specifically, alongside cyber security software, remote monitoring systems, and patient engagement tools as the areas earmarked for the strongest growth. Each of these tells its own story about where NHS priorities are heading. Ambient voice technology, which automatically listens to and documents clinical consultations, has moved from pilot curiosity to genuine procurement category in a remarkably short space of time. It sits squarely inside the productivity narrative Sargeant described: it doesn't require new clinical headcount, it directly attacks one of the most persistent drains on clinician time (documentation), and it can be deployed incrementally across existing EPR infrastructure rather than requiring a rip and replace programme. Expect continued consolidation and expansion in this category as trusts move from pilots to at scale rollout. Cyber security spend, meanwhile, reflects a threat landscape that has only intensified. The NHS has experienced a string of high-profile ransomware and supply-chain incidents in recent years, several of which caused significant clinical disruption, and cyber resilience has become a board-level and regulatory priority rather than a purely technical one. Growth here is less discretionary than in other categories, it's substantially compliance and risk-driven, which tends to make it a more defensible long-term revenue line for suppliers than categories more exposed to policy or funding swings. Remote monitoring and patient engagement tools both point toward a shift in where care is delivered and who is expected to manage it. Virtual wards, remote monitoring of long-term conditions, and digital front door tools for patient access and self management all reduce reliance on physical estate and face to face capacity, both of which are far more expensive and far slower to expand than software licences. As the NHS continues to grapple with elective backlogs, ageing infrastructure, and constrained capital budgets, technology that shifts care out of buildings and into homes carries an obvious appeal. How FHI Builds the Forecast It's worth understanding the methodology behind these numbers, because it shapes how much weight to put on them. The FHI Market Model isn't a survey-based estimate or a simple extrapolation of historical trend lines. It draws on analysis of actual procurement awards, contracts that have been signed and published, combined with supplier financial data, to build a picture of current local NHS IT spending across the five categories described above. That bottom-up, evidence based starting point is then projected forward using published government spending plans and stated policy commitments, rather than FHI's own assumptions about what should happen. This matters because it means the £8.3bn 2030 figure isn't a hopeful industry projection; it's derived from money the government has already committed to spending, layered on top of observed current spending patterns and known procurement activity. That doesn't make it immune to disruption, spending review outcomes, changes in NHS financial planning, or a change in government priorities could all move the number, but it does mean the forecast has a firmer evidential footing than the kind of top-down market-sizing exercises that are common (and commonly wrong) in health tech. The Baseline: What We Already Know About NHS Trust IT Spend The 2030 forecast builds on FHI's earlier analysis, published in February 2026, which found that total IT spend by NHS trusts across the UK reached £4.1bn in 2024/25, a 9% increase on the previous year. That single data point is worth pausing on: a 9% year-on-year increase is, by any standard, rapid growth for a public sector spending category, and it suggests the acceleration FHI is now forecasting through to 2030 isn't a break from recent trend but a continuation of one already underway. The February analysis also sheds useful light on where that spending is actually happening. England accounted for 87% of total UK local NHS trust IT spending in 2024/25, an outsized share relative to England's roughly 84% share of the UK population, reflecting both the scale of the English NHS and the intensity of its digital transformation programmes relative to the devolved health services in Scotland, Wales, and Northern Ireland. Within England, the split by trust type is heavily skewed toward acute care: acute trusts accounted for 80% of local NHS IT spending, with mental health trusts responsible for 18% and community trusts just 2%. That imbalance is a familiar and long standing feature of NHS digital investment, and one that periodically attracts criticism from mental health and community care advocates who argue their sectors remain digitally under-resourced relative to acute care despite carrying significant and growing caseloads. Given the strong growth forecast for remote monitoring and patient engagement tools, categories that arguably have as much or more relevance to community and long-term condition management as to acute episodic care, it will be worth watching in future FHI updates whether that 80/18/2 split begins to shift, or whether acute trusts continue to capture a disproportionate share of new digital investment even in categories theoretically suited to community deployment. Who's Spending the Most FHI's trust-level data also names names. Guy's and St Thomas' NHS Foundation Trust recorded the highest IT spend of any acute trust in 2024/25, at £109m. Manchester University NHS Foundation Trust followed at £90m, with University Hospitals Birmingham NHS Foundation Trust third at £68m. There's a pattern worth noting here beyond the raw rankings: all three are large, multi-site acute trusts serving major urban populations, each of which has been through significant EPR and digital infrastructure investment in recent years. Guy's and St Thomas', for instance, has been one of the more prominent adopters of advanced digital and AI-enabled clinical tools in the NHS, and its position at the top of the spending table is consistent with a broader pattern where the trusts with the most mature digital strategies also tend to be the biggest spenders, digital maturity and digital investment reinforce one another rather than digital investment simply "catching up" less mature organisations to the leaders. For suppliers and investors assessing where to focus commercial effort, this concentration of spend among a relatively small number of large, digitally sophisticated trusts is a significant structural feature of the market: it rewards vendors who can build credibility and reference deployments with tier-one trusts, since those relationships tend to be both the largest contracts and the most influential in shaping wider market perception. What This Means for the Market Step back from the individual data points and a coherent picture emerges. This is a market growing faster than the wider public sector, growing for structural rather than cyclical reasons, and growing in a reasonably predictable, policy anchored way rather than through one off funding windfalls. For companies operating in or adjacent to NHS IT, software vendors, systems integrators, managed service providers, and the investors who back them, that combination of scale, growth rate, and predictability is unusual and valuable. It also has clear implications for how the market is likely to consolidate over the coming years. A sector forecast to add over £2bn in new spend by 2030, concentrated heavily in software and services rather than hardware, and skewed toward categories like AI-enabled clinical tools, cyber security, and remote care, is precisely the kind of environment that tends to attract private equity and strategic acquirers looking to build scale, broaden product portfolios, or buy their way into categories with strong structural tailwinds. Smaller specialist vendors in ambient voice technology, remote monitoring, and patient engagement in particular are likely to see increased acquisition interest as larger health tech platforms and international entrants look to establish or consolidate a UK NHS footprint ahead of the growth FHI is now forecasting. Trusts' own reorganisation-driven reliance on external suppliers, as Sargeant noted, only adds to the appeal of building scaled service capability that can be deployed flexibly across a changing NHS structure. There are, of course, real risks to the forecast holding. A change in government spending priorities under a new prime minister, a disappointing spending review settlement, or a renewed bout of NHS financial distress leading to short-term capital and IT budget freezes have all disrupted digital investment plans before, sometimes sharply. FHI's own framing acknowledges this uncertainty even as it maintains confidence in the underlying trajectory. But the structural case for continued NHS IT growth — an ageing population, a workforce that cannot expand indefinitely, and a political consensus (however contested at the margins) that productivity gains must come from somewhere — remains intact regardless of who occupies Downing Street. For now, the direction is clear. From £6.1bn to £8.3bn in five years, with software, AI-enabled clinical tools, cyber security, and remote care leading the charge: the NHS IT market looks set to remain one of the more compelling growth stories in UK public sector technology for the rest of this decade. Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns.www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA#Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk

Nelson Advisors: Digital Health Venture and Growth Equity firm Transformation Capital Closes Fund IV at $850 Million, Exceeding Its Target in Oversubscribed Fundraise Transformation Capital, the largest dedicated digital health venture and growth equity firm, has announced the final close of its fourth fund, Transformation Capital Fund IV, at an $850 million hard cap. The raise came in oversubscribed, with the firm completing the close this summer after exceeding its original target. It's a milestone that says as much about the state of digital health investing in 2026 as it does about Transformation Capital itself, and it's worth unpacking both the headline number and what sits behind it. A Hard Cap, Hit and Exceeded In venture and growth equity, a "hard cap" is the absolute ceiling a firm sets for how much capital it will accept into a fund, regardless of investor demand. Closing at that hard cap, rather than somewhere below it, signals that a firm had to turn away or scale back interest from investors who wanted in. An oversubscribed close is the clearest form of validation a fund manager can receive: it means the market, in this case a highly specialised community of institutional allocators, looked at the strategy, the team and the track record and decided there was more capital chasing the opportunity than the firm was willing to accept. Fund IV's LP base tells a two-part story. On one hand, existing limited partners returned to back the strategy again, a strong signal of satisfied capital allocators who have presumably seen results from Transformation Capital's earlier funds and wanted to double down. Re-ups from existing LPs are often viewed within the institutional investment community as one of the more reliable proxies for a manager's performance, since existing investors have visibility into a fund's marks, distributions and portfolio company trajectories that outside observers don't. On the other hand, Fund IV also pulled in a wave of new institutional investors coming to Transformation Capital for the first time. That combination, loyal existing capital plus fresh institutional demand, is generally what pushes a raise past its original target and toward a hard cap. It suggests the firm's story is resonating not just with people who already know it, but with a broader universe of allocators newly convinced that digital health, and specifically the AI driven subset of it, deserves a larger allocation within their portfolios. The firm has already begun putting Fund IV capital to work in new partner companies, meaning the fund is not sitting on dry powder waiting for a deployment plan. It is actively sourcing and closing deals, which matters in a market where the best founders often run tight, competitive processes and expect committed capital to move quickly. Scaling to $2.5 Billion Across Four Funds With Fund IV's close, Transformation Capital's total assets under management now exceed $2.5 billion across its four funds. That figure places the firm among the more substantial dedicated players in the digital health investment landscape, a category that includes both specialist funds and generalist healthcare-focused vehicles housed within larger multi-sector firms. Being described as the "largest dedicated digital health venture and growth equity firm" is a meaningful positioning claim. It distinguishes Transformation Capital from healthcare-focused funds that sit inside broader generalist platforms, and from digital health-adjacent funds that invest opportunistically rather than as a core, singular mandate. A firm that has built its entire identity, deal sourcing network, operating expertise, and reputation around one vertical for close to two decades occupies a different position in the market than a firm treating healthcare as one sector among several. Scaling from whatever the firm's earlier funds totalled to $2.5 billion in cumulative AUM also reflects the broader maturation of digital health as an asset class. Healthcare technology investing was, for a long stretch of the 2010s, viewed with some skepticism by institutional allocators who worried about long sales cycles, regulatory complexity and reimbursement uncertainty. The growth of specialist funds like Transformation Capital to multibillion dollar scale is itself evidence that those early concerns have given way to a more confident, better informed institutional consensus that digital health is a durable, investable category with its own playbook. Four Waves of Change Since 2009 What gives Transformation Capital's positioning particular credibility is the firm's framing of its own history against the arc of U.S. healthcare transformation since 2009. According to the firm, healthcare has moved through four successive waves of change over roughly a decade and a half, and Transformation Capital has invested behind each one. The first wave was the digitisation of medical records. Following the passage of the HITECH Act in 2009, which created financial incentives for healthcare providers to adopt electronic health records, the industry underwent a foundational shift away from paper charts. This wave didn't just change how information was stored; it created the data infrastructure that every subsequent wave of healthcare innovation has depended on. Without digitised records, there is no meaningful data exchange, no population health analytics and ultimately no AI applications capable of reasoning over clinical information at scale. It was, in other words, the plumbing wave, unglamorous but essential. The second wave was the shift toward value-based payment models. For decades, the dominant reimbursement logic in American healthcare was fee-for-service: providers were paid for the volume of services rendered, not the quality of outcomes achieved. Beginning in earnest in the 2010s, driven by both public programs like Medicare's Accountable Care Organization initiatives and private payer experimentation, the industry began building alternative payment structures that tied reimbursement to outcomes, cost containment, and quality metrics. This realignment of financial incentives created enormous demand for technology and services companies that could help providers and payers actually manage risk, track outcomes and coordinate care in ways the old fee-for-service system never required. The third wave was the pandemic driven adoption of telehealth. Virtual care existed in limited forms before 2020, but COVID-19 compressed what might have been a decade of gradual adoption into a matter of weeks. Regulatory waivers, reimbursement parity rules, and sheer necessity pushed both patients and providers to embrace video visits, remote monitoring and asynchronous care models almost overnight. While some of the most extreme pandemic era usage has normalised since, telehealth's core premise, that a meaningful share of care can and should happen outside a physical exam room, has proven durable rather than temporary. It fundamentally expanded what "access to care" means in a way that has stuck. The fourth and most recent wave, per the firm's own framing, is the rapid embrace of artificial intelligence to attack what Transformation Capital describes as more than $1 trillion in waste and inefficiency embedded in the U.S. healthcare system. That trillion dollar figure aligns with a body of health economics research over the past decade estimating that a substantial share of total US healthcare spending, which itself runs into the trillions of dollars annually, is attributable to administrative complexity, unnecessary or duplicative services, fraud, pricing failures and other forms of waste rather than value-generating clinical care. AI, in this framing, is not simply another category of health tech innovation; it is positioned as the most credible tool yet developed for systematically identifying and eliminating that waste, whether through automating administrative workflows, optimising clinical decision making, streamlining prior authorisation and billing processes, or improving the efficiency of care delivery itself. Eight New AI Investments in a Single Year Transformation Capital says it made eight new AI focused investments in the past year alone and that Fund IV will continue that strategy. That pace of activity, essentially one new AI-focused deal roughly every six to seven weeks, reflects both the sheer volume of AI native healthcare startups now coming to market and the firm's evident conviction that this fourth wave represents the current centre of gravity for digital health innovation. It's worth noting what kind of AI investing this represents. Transformation Capital's stated strategy is to back "commercial stage companies," a meaningful qualifier. This is not primarily a firm making early, speculative bets on unproven technology or funding academic research projects in the hope they eventually find commercial traction. It is backing companies that have already demonstrated they can sell into and operate within the notoriously complex world of healthcare commercial channels, health systems, payers, employers, pharmacy benefit managers and increasingly, direct to consumer and direct to employer channels and are using technology and AI specifically to make healthcare more efficient, more accessible and more accountable. That three-part framing, efficiency, accessibility and accountability, functions almost as an investment thesis in miniature. Efficiency speaks to the administrative and operational waste the firm has identified as its core opportunity. Accessibility speaks to the access-expanding legacy of the telehealth wave, ensuring that gains in reaching underserved populations and geographies aren't lost as the industry's attention shifts toward AI. Accountability speaks to the outcomes and value-based care lineage, a recognition that technology deployed in healthcare needs to be measurable, auditable and tied to real clinical and financial results, not simply impressive in a product demo. What Draws Founders Beyond the Capital The release notes that Transformation Capital's strategy has made it "a magnet for some of the sector's most sought-after founders," and is careful to add that this isn't only because of the capital on offer, but because of what comes with it. This is a common and important distinction in specialist venture investing, particularly in a vertical as operationally complex as healthcare. Generalist capital is increasingly a commodity. Founders building in healthcare, especially those navigating regulatory approval pathways, payer contracting, clinical validation studies and health system procurement cycles that can stretch on for twelve to eighteen months or longer, tend to place a premium on investors who understand those dynamics natively rather than investors who need the landscape explained to them in every board meeting. A dedicated digital health investor with nearly two decades of pattern recognition across four distinct waves of industry transformation, and a portfolio built specifically around commercial stage healthcare AI companies, is in a position to offer something a multi-sector fund typically cannot: genuine operating fluency in how healthcare businesses actually get built, sold and scaled. For founders evaluating where to take capital, that kind of specialist credibility often translates into practical advantages that go well beyond the check itself: warm introductions to health system and payer decision makers who trust the investor's judgment, informed guidance on regulatory and reimbursement strategy, a network of portfolio companies and executives who have already solved similar go to market problems, and an investor base of co investors and LPs who are themselves fluent in the sector's particular rhythms. In a fundraising environment where the most promising commercial stage healthcare AI companies can often choose among multiple term sheets, that combination of capital plus sector specific value tends to be the deciding factor. What Fund IV Signals for Digital Health Investing Transformation Capital's $850 million close arrives at a moment when digital health investing as a category has matured considerably from its more volatile years. The sector saw a dramatic funding surge in 2020 and 2021, driven substantially by pandemic era telehealth enthusiasm, followed by a sharp correction in 2022 and 2023 as valuations reset and investors grew more disciplined about unit economics, regulatory risk, and genuine commercial traction rather than growth at any cost. Fund IV's oversubscribed close, backed by both loyal existing LPs and a wave of new institutional capital, is a signal that sophisticated allocators view the current environment, anchored by AI's applicability to healthcare's enormous inefficiency problem, as a genuinely attractive entry point rather than a repeat of the earlier hype cycle. The firm's explicit framing of AI as the fourth wave in a continuous, decade-and-a-half arc of healthcare transformation, rather than as a standalone trend disconnected from what came before, is also a useful lens for the broader market. It suggests that the most durable AI opportunities in healthcare are likely to be those that build on the data infrastructure created by EMR digitisation, align with the incentive structures created by value-based care and extend the access gains created by telehealth, rather than AI applications that exist in isolation from those earlier structural shifts. With Fund IV's capital already flowing into new partner companies, and a track record of eight AI-focused investments in the past year alone, Transformation Capital appears positioned to remain one of the more active and influential capital allocators in digital health AI over the coming several years. For the founders building commercial stage companies aimed at healthcare's trillion dollar waste problem, and for the broader industry watching where specialist capital is placing its confidence, Fund IV's oversubscribed close at its $850 million hard cap is a data point worth paying attention to. Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns.www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA#Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk

Nelson Advisors: Apple acquires Sonera under the radar to build new sensing capabilities into its hardware Apple Just Bought a Company That Can Read Your Brain's Magnetic Signals, Quietly There was no keynote, no press release, no carefully art-directed product shot. Apple's latest acquisition surfaced the way most of its acquisitions do: through a regulatory filing nobody was supposed to notice. Buried in the European Union's database of mergers likely to be significant in the region, a single entry revealed that Apple had acquired Sonera, a Berkeley born startup that builds non-invasive sensors capable of reading neural signals straight from the brain and body. The deal reportedly closed in May 2026. Apple has said nothing about it publicly. Sonera's own website has quietly gone dark. And yet this may turn out to be one of the more consequential acquisitions in Apple's recent history, because it points toward a future in which your Apple Watch, or whatever comes after it, doesn't just track your heart rate. It reads your muscles, and possibly your thoughts. Who Is Sonera, and What Does It Actually Make? Sonera was founded in 2018 by Nishita Deka and Dominic Labanowski, two UC Berkeley students who set out to solve a problem that has quietly limited the entire field of brain-computer interfaces: the tools for reading neural activity are either too invasive, too expensive, or too imprecise for everyday use. Operating for years under the name Sonera Magnetics, the company stayed in stealth mode until September 2023, when it emerged with $20 million in funding, an $11 million seed round led by Amplify Partners, with participation from Abstract Ventures, Spark Capital, Material Impact and Boom Capital. Notably, one of its angel investors was Josh Duyan, a co-founder and former chief science officer at CTRL-Labs, the neural-interface company Facebook (now Meta) acquired in 2019 for a reported $500 million to $1 billion. That pedigree matters: CTRL-Labs' wristband technology, which reads electrical signals from motor neurons to translate intention into digital input, is one of the most cited precedents for exactly the kind of consumer neural interface Sonera has been chasing, except Sonera took a different physical approach to get there. Where most neural sensing technology, EEG caps, EMG electrodes, the surface sensors used in research labs and in products like CTRL-Labs' band, relies on detecting the electrical activity generated by nerves and muscles, Sonera built its technology around magnetic fields instead. As co-founder Nishita Deka put it when the company came out of stealth, the goal was "to detect brain activity using cheaper, faster methods that are still high-performance." Every electrical signal in the body, including the ones firing between neurons and the ones activating your muscles, generates a tiny corresponding magnetic field. Traditional brain-imaging techniques that read these magnetic fields, such as magnetoencephalography (MEG), have existed for decades, but they typically require room-sized machines, magnetically shielded chambers, and equipment that costs millions of dollars. Sonera's pitch was that it could shrink that capability down into something closer to chip scale. The advantage of the magnetic approach over electrical sensing is a genuinely interesting piece of physics. Electrical signals get distorted and dampened as they pass through the skull, skin, hair, and other tissue, which is why EEG readings are famously noisy and why electrode-based sensors typically need direct, often gel-assisted, contact with the skin to get a clean signal. Magnetic fields, by contrast, pass through tissue and even through clothing with far less distortion. That means a magnetic sensor can, in principle, sit near the body rather than directly on it, and still pick up a higher-fidelity signal than an electrical sensor pressed right up against the skin. It's the difference between trying to hear a conversation through a wall versus feeling the vibration of it and Sonera built its business on the bet that the vibration-based approach could eventually be made cheap enough, and small enough, to live inside a consumer gadget. The S1 Chip Sonera's first commercial product, and the clearest signal of where the company was headed before Apple came calling, was the S1 chip. Despite the company's original framing around brain activity, the S1's initial application target was muscle sensing rather than direct brain reading, arguably the more tractable, nearer-term problem, since muscle signals are stronger and easier to isolate than the faint magnetic traces produced by neurons deep in the brain. According to Sonera's own materials, the S1 works by measuring the magnetic fields generated by the electrical currents produced during neural and muscular activity, without requiring the sensor to touch the skin directly. That is a meaningfully different proposition from today's optical heart-rate sensors or electrical EMG patches, which generally need skin contact to function well. Sonera positioned the S1 as a foundation technology rather than a single-purpose gadget, and the company talked about several concrete use cases: control of advanced prosthetic limbs, continuous monitoring of neuromuscular conditions such as ALS, muscular dystrophy, or Parkinson's-related tremor, biomarker discovery for neurological and muscular disease research, and sports and fitness performance tracking based on real muscle activation patterns rather than proxies like heart rate or accelerometer data. And crucially, in its own words, the company described the S1 as capable of enabling "an entirely new class of consumer wearables and experiences based on muscle activity", a line that, in hindsight, reads almost like a pitch deck slide aimed squarely at a company like Apple. Beyond muscle sensing, Sonera also described its underlying platform as capable of registering brain magnetic activity directly, and suggested the technology could eventually support "thought control" of devices — using detected neural signals as an input method, similar in spirit to what Neuralink is pursuing with implanted electrodes, or what Meta has explored with the wristband technology it inherited from CTRL-Labs, but without surgery and without needing the device to sit on bare skin. That's a much longer-term and technically harder target than muscle sensing, and there is no public evidence yet that Sonera had a working consumer-grade product for brain-signal decoding rather than muscle-signal decoding. But it was clearly the company's north star, and it's a large part of why an acquisition by Apple looks significant rather than incidental. How the Deal Came to Light Apple has a long-standing habit of acquiring small companies quietly and saying almost nothing about it, a practice that dates back years and has been true of dozens of deals, from Beddit, the sleep-tracking company Apple bought in 2017, to various AI, chip, and camera-technology startups absorbed with barely a public trace. Apple's standard line when asked about acquisitions, repeated by executives for over a decade, is that the company "buys smaller companies from time to time" and generally doesn't discuss its purpose or plans. Sonera appears to be following that exact playbook: no announcement, no confirmation, and by the time the deal became visible, Sonera's website had already been taken offline, scrubbing the public record of the company's own description of its technology. What forced this deal into daylight wasn't a leak or an SEC filing, it was European regulation. The European Union maintains a public database tracking mergers and acquisitions that could be significant enough to warrant regulatory scrutiny within its jurisdiction, part of its broader push for transparency around large companies' acquisition activity, particularly under scrutiny tied to the Digital Markets Act, which designates Apple as a "gatekeeper" subject to heightened oversight. That listing showed the Apple-Sonera transaction closing in May 2026, meaning the deal had already been finalized for roughly four months before it became publicly visible in September. It's a pattern that has become almost routine for Apple-watchers: some of the company's most interesting recent acquisitions have come to light not through Cupertino's own disclosures, but through the EU's regulatory paper trail, because Apple's size now means very few of its deals can stay entirely invisible, even when the company would clearly prefer that they did. Why the Apple Watch Is the Obvious Landing Spot Apple has spent the better part of a decade turning the Apple Watch from a notification-and-fitness accessory into something closer to a genuine health-monitoring platform. Blood oxygen sensing, ECG readings, fall detection, irregular heart rhythm notifications, temperature sensing for cycle tracking, and increasingly ambitious rumored features around hypertension and sleep apnea detection have all followed the same basic trajectory: take a capability that used to require a clinical device and shrink it down into something that lives on your wrist and runs quietly in the background. Muscle and neural sensing fits that trajectory almost perfectly, and it would address a category of health conditions the Watch currently does very little for. Continuous, passive monitoring of neuromuscular conditions is the most plausible near-term application. Conditions like Parkinson's disease, essential tremor, multiple sclerosis, and ALS are typically tracked through periodic clinical assessments — a patient visits a specialist every few months, and the doctor evaluates symptoms based on a brief snapshot in time. A wrist-worn sensor capable of picking up subtle changes in muscle activation patterns over weeks and months could, in principle, give both patients and physicians a continuous data stream instead of occasional spot-checks, catching disease progression or medication effectiveness far earlier than an occasional office visit ever could. That's a genuinely compelling accessibility and healthcare pitch, and it lines up with Apple's broader positioning of the Watch as a device that can meaningfully affect people's health outcomes, not just their step counts. There's also a plausible interaction-design angle. Apple has already shipped a feature called Double Tap on the Apple Watch, which uses the existing accelerometer, gyroscope, and optical heart sensor to detect the subtle wrist motion of tapping your index finger and thumb together, letting users answer calls or dismiss notifications without touching the screen. That feature is a crude, indirect ancestor of what Sonera's technology could enable far more precisely: reading actual muscle activation signals to detect intended gestures, even extremely subtle ones, with much higher accuracy and a much richer vocabulary of possible inputs than an accelerometer can infer. It's not hard to imagine a future Apple Watch, or a future wearable entirely, using magnetic muscle sensing as a general-purpose silent input method, useful for accessibility, for AR and VR interaction (an area where Apple has already invested heavily with Vision Pro), and simply for controlling a device without having to look at it or touch it. The brain-signal side of Sonera's technology is a far more speculative and distant prospect for a consumer Apple product and it's worth being skeptical about near-term claims of "thought control" showing up in anything Apple ships soon. Reading usable, reliable signals directly from brain activity, even with a fundamentally better sensing approach, is an extraordinarily hard problem, and companies far more singularly focused on it, Neuralink most prominently, though that requires a surgical implant, have taken years to get to even limited real-world deployment. It's much more likely that Apple acquired Sonera primarily for the muscle-sensing capability that already exists in a shipping-adjacent chip, with the brain-sensing research representing a longer-horizon bet that may or may not pay off, rather than a near-term feature roadmap. The Bigger Picture This acquisition also fits a recognisable pattern in how Apple builds new sensing capabilities into its hardware. The company rarely invents entirely new sensor physics in-house; instead, it tends to acquire small teams that have already done the hard, unglamorous work of shrinking a specialised capability down to something approaching commercial viability, then spends years quietly integrating that technology, refining its manufacturing, and building the software and privacy infrastructure around it before it ever appears in a keynote. Blood oxygen sensing, the underlying technology in AirPods' hearing health features, and elements of the Watch's ECG capability all trace back to smaller acquisitions or licensing deals that predated their public debut by years, sometimes with no public link drawn between the acquisition and the eventual feature until well after the fact. There are real questions worth sitting with here too, separate from the technical excitement. Neural and muscular signal data is about as sensitive as personal data gets, arguably more sensitive than location or even health records in the traditional sense, because it captures something closer to intention and involuntary physiological state rather than just an outcome or a measurement. How that data would be processed, whether it stays on-device in the way Apple has positioned much of its health data processing, and what regulatory frameworks would even apply to consumer-grade neural sensing are all open questions that will matter enormously if this technology does eventually ship in a mainstream product. Apple's public silence on the acquisition means none of that has been addressed yet, and likely won't be until, and unless, the company is ready to talk about an actual product. Where Sonera Fits Among the Brain Computer Interface Players It's worth placing Sonera on the broader map of companies chasing brain and neuromuscular interfaces, because the field has quietly become crowded, and the approaches diverge sharply. Neuralink, Elon Musk's company, sits at the most invasive end of the spectrum, implanting electrode arrays directly into the brain via surgery, chasing extremely high-fidelity signal in exchange for real medical risk, a trade-off that makes sense for patients with severe paralysis but is a nonstarter for a mass-market consumer device. Meta's CTRL-Labs technology, inherited through its 2019 acquisition, sits in the middle: a wristband reading electrical signals from motor neurons, non-invasive but still dependent on skin contact and electrical sensing's inherent noisiness. Companies like Precision Neuroscience have pursued thinner, less invasive implants that sit on the brain's surface rather than penetrating it, another middle-ground approach. Sonera's bet was that magnetic sensing could leapfrog all of these trade-offs at once, no surgery, no required skin contact, and a cleaner signal than electrodes can typically achieve, which is precisely the combination that would make a neural or neuromuscular interface plausible inside a mainstream consumer wearable rather than a medical device or research tool. Whether Sonera had actually closed the gap between that ambition and a manufacturable, battery-efficient chip at Apple Watch scale is exactly the kind of question an acquisition like this is meant to answer, quietly, over the next several product cycles. For now, what we have is a regulatory filing, a defunct company website, and a trail of technical claims Sonera made about its own S1 chip before it went quiet. It's enough to draw a credible picture of where Apple might be headed, deeper into the body's own electrical and magnetic signals as the next frontier of wearable health tracking, but not enough to say with confidence what that will look like in an actual product, or when. Given Apple's typical timelines for turning an acquired sensing technology into a shipping feature, anything built on Sonera's work is more likely to be a story for 2027 or beyond than for this year's Apple Watch. But the direction is now unmistakable: Apple wants to know not just how fast your heart is beating, but what your muscles, and maybe eventually your mind, are doing too. Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns.www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA#Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk

Tandem Health's $100M Series B: Europe Finally Has a Healthcare AI Champion and the AVT Market Is About to Consolidate Around It Executive Summary On 14th September 2026, Stockholm-based Tandem Health announced a $100 million (€86.5 million) Series B led by the Scaleup Europe Fund, the €5 billion vehicle managed by EQT and seeded by the European Commission, Novo Holdings, CriteriaCaixa and Santander. Existing backers Kinnevik, Northzone, Amino Collective and Visionaries all followed on. The round takes Tandem's total funding to roughly $160 million, barely fifteen months after its $50 million Series A and makes it the best-capitalised clinical AI company headquartered in Europe. The headline number matters, but three things matter more. First, this is the Scaleup Europe Fund's first healthtech deal, sitting alongside Mistral and Iceye in a portfolio explicitly designed to build European champions in strategic technologies. Healthcare AI has just been designated strategic infrastructure by the EU's own scale-up capital. Second, Tandem is no longer describing itself as an ambient scribe. The stated ambition is an "AI-native operating system for European healthcare," which reframes the company from a documentation tool into a platform that intends to own the clinical workflow. Third, Tandem has already shown it will buy rather than build where that is faster, having acquired Dutch market leader Juvoly in January 2026. With $100 million of fresh capital and a mandate to consolidate, the acquisition question is not whether but who, where and how soon. This article examines what the raise tells us about the European healthcare AI market, what it means for the crowded field of ambient voice technology (AVT) competitors, and where Tandem is most likely to deploy acquisition capital over the next eighteen months. 1. The Deal in Context Tandem Health was founded in 2023 by Lukas Saari (CEO), Oscar Boldt-Christmas (CCO) and Oliver Åstrand (CTO). In three years it has grown to around 170 employees, more than 75 in-house clinicians, and a footprint across 14 European markets. The company reports that its platform is now used across 10,000 care organisations, with the UK its largest market by user numbers, and marquee customers including Ramsay Santé in France, Humanitas in Italy and the NHS. Much of the UK footprint comes through the Accurx partnership, under which Tandem's engine powers Accurx Scribe for GP practices, giving it distribution into primary care that a Scandinavian start-up could never have built directly. The product has moved well beyond note generation. Tandem's AI scribe, coding support and clinical decision support are each independently certified as Class IIa medical devices under the EU Medical Device Regulation, and the company holds ISO 27001, ISO 13485 and ISO 42001 alongside country-specific attestations such as C5 in Germany, ENS High in Spain and HDS in France. That certification stack is expensive and slow to assemble, with MDR certification alone typically costing €200,000 to €600,000 and taking 12 to 18 months, and it is precisely the kind of moat that separates platforms from features. The clinical evidence is respectable if not yet definitive. Tandem cites a 29% reduction in administrative time, a 30% improvement in job satisfaction and a 30% reduction in administrative stress among clinicians using the product. Earlier NHS audits reported a 97% clinical accuracy rate for generated notes. These are the numbers procurement committees now demand, and they explain why Tandem was one of the 19 suppliers listed on NHS England's Ambient Voice Technology self-certified supplier registry when it launched in January 2026. The Series A was led by Kinnevik. A Series B led by an EU mandated fund is a different kind of endorsement. Saari's line that "Europe should be setting the standard for how AI enters healthcare, not adopting someone else's" is not just founder rhetoric; it is the investment thesis of the lead investor. 2. What This Means for the European Healthcare AI Market Sovereignty has become an investable theme For most of the last decade, European digital health has been characterised by fragmented national markets, slow procurement and capital that was thin relative to the United States. That picture is changing, and Tandem's round is the clearest evidence yet. The Scaleup Europe Fund exists because European policymakers concluded that late-stage growth capital was the missing piece in the continent's technology stack. Its decision to make healthtech its third sector, after foundation models and space, signals that clinical AI is now viewed as sovereign infrastructure in the same way as Mistral's language models. This has practical consequences. US leaders such as Abridge, valued at $5.3 billion, and Microsoft's Dragon Copilot have the balance sheets to enter Europe, and Microsoft did so with its UK launch in September 2025. But they face buyers who increasingly ask where data is processed, whether the model has been validated in the local language and against local guidelines, and whether the vendor lives under the EU AI Act as a native rather than an importer. Tandem's certification portfolio, in-country compliance attestations and EU-backed cap table make it the obvious answer for hospital groups and national systems that want a European-first platform. Capital is polarising, not disappearing European digital health funding fell 44% year-on-year in the first quarter of 2026, with deal count down 46%. Yet the average deal size rose to $21.1 million, and Tandem has just raised a round that on its own exceeds most of the quarter's activity in the segment. The market is not contracting so much as concentrating. Money is available for platforms with clinical evidence, regulatory clearance and multi-country traction, and largely unavailable for single-country scribes without a differentiated position. When a category leader raises a round an order of magnitude larger than the median, the rest of the field is forced to raise from a shrinking pool, find a strategic home, or fade. European ambient AI is now entering that phase. The category is being redefined from scribe to operating system Every serious player in the space is now saying the same thing, that the scribe is a wedge rather than a business. Nabla describes its ambition as "agentic AI at the heart of clinical workflows." Heidi Health talks about the clinician AI stack. Microsoft reframed Dragon Copilot as an agentic clinical assistant at HIMSS 2026. Tandem's "AI-native clinic operating system" language, with explicit reference to patient flow management and agents for additional clinical tasks, places it squarely in that race. The reason is commercial as much as technical. A standalone scribe is priced per clinician per month and is easily substituted. An operating system that handles documentation, coding, decision support, referrals and patient flow becomes embedded in the revenue cycle and the safety case of the organisation, which is where durable contracts and pricing power live. Regulation is doing the sorting The EU MDR, the AI Act, NHS England's DTAC and the AVT registry criteria have collectively raised the cost of participation. The MHRA's clarification that AVT with summarisation is a Class I device, and Class IIa where the software suggests management plans or referrals, means anyone wanting to move beyond transcription needs the same certifications Tandem already holds. NHS England has openly warned trusts and practices against unregistered products. The result is what some commentators have called regulatory Darwinism: a small number of compliant, well-capitalised platforms are being handed structural advantages, and the long tail is being pushed towards acquisition or exit. 3. Impact on AVT Competitors The European AVT field can be sorted into four groups, and Tandem's raise affects each differently. The global platforms: Microsoft, Heidi, Abridge Microsoft Dragon Copilot arrived in the UK in September 2025 with distribution through Microsoft 365, deep EPR partnerships and a two-decade Nuance heritage in dictation. It remains the incumbent to beat in acute hospitals. Tandem's raise does not change Microsoft's position directly, but the European alternative now has the capital to compete on implementation depth and country-specific compliance rather than simply on price. Heidi Health is the most interesting comparator. The Melbourne-based company raised a $65 million Series B in October 2025 at a $465 million valuation, acquired UK clinical decision support start-up AutoMedica in February 2026, and in July 2026 won the Midlands regional procurement covering all 1,239 GP practices and more than 70,000 clinicians across 15 trusts. Heidi and Tandem are now fighting for the same NHS primary care estate, with Heidi holding the largest single regional contract and Tandem holding the largest installed base through Accurx. Tandem's $100 million is a direct response to that competitive dynamic, and we should expect Heidi to return to the market for a larger round before long. Abridge has so far concentrated on US health systems. Language, MDR and national data rules make an acquisition of a European player its most likely route into the continent, which makes Abridge both a competitor to Tandem and a potential bidder for the same assets. The European venture-backed peers: Nabla, Corti, voize Nabla in Paris has raised roughly $120 million including a $70 million Series C in June 2025, but has directed most of its commercial energy at the United States, where it has landed health system contracts such as M Health Fairview. Tandem's round means Nabla is no longer the best-funded European-born player, and it raises the question of whether Nabla doubles down on America or comes back to defend its home market. A strategic combination between the two is not unthinkable, though cultural and investor dynamics make it unlikely near term. Corti in Copenhagen is the closest Nordic rival, with a long history in emergency call triage and a growing ambient product that sits on the NHS registry. Corti has positioned itself increasingly as an infrastructure and API provider to other vendors rather than a direct clinician-facing brand, which could make it either a partner or a target depending on how its next financing goes. voize in Berlin raised a $50 million Series A in November 2025 and has focused on nursing and care homes, a segment that is less contested and adopting rapidly. It is the strongest German-language player and the most natural acquisition for anyone wanting instant depth in DACH long-term care. The UK specialists: Tortus, Anathem, Scribetech, T-Pro, Dictate IT, Lexacom The UK has more registered AVT vendors than any other European country, and most are sub-scale relative to Tandem. Tortus AI has strong clinical credibility from its GOSH-led London trials, but has raised under $10 million and faces a choice between a difficult Series A and a strategic partner. T-Pro, Dictate IT and Lexacom bring legacy dictation revenue and installed bases in NHS trusts, exactly the distribution a platform wants. For all of them, Tandem's raise compresses the window in which an independent path remains credible. The incumbents and platforms: Accurx, Doctolib, EMIS/Optum, EPR vendors The most consequential competitors may not be scribes at all. Doctolib acquired Medicus, the first new NHS-approved GP IT system in 25 years, in March 2026 as part of a £100 million UK push, and is building AI documentation into its consultation software in France and Germany. Optum's EMIS is on the AVT registry in its own right. Every EPR vendor is bundling or partnering for ambient capability. Standalone scribes that live outside the record are structurally disadvantaged against tools embedded in it, which is why Tandem's operating system framing and its Accurx relationship matter so much. The uncomfortable question for Tandem is how long Accurx remains a partner rather than a competitor, and whether the Series B gives Tandem the means to reduce that dependency by owning more of the UK stack directly. Tandem Health's $100M Series B: Europe Finally Has a Healthcare AI Champion and the AVT Market Is About to Consolidate Around It 4. The Acquisition Playbook: Where Tandem Buys Next Tandem has described the Juvoly deal as "Europe's first acquisition of an AI scribe company focused on clinical workflows." Juvoly served more than 1,500 Dutch GP practices, around 35% of Dutch primary care, and processed over 200,000 consultations a month. The logic was simple: buy the local leader, keep the team, plug in Tandem's certified engine and platform, and skip two years of country-by-country go-to-market. That template is highly repeatable, and with $100 million in the bank and a strategic investor that wants a pan-European champion, we expect Tandem to run it several more times. Five categories of target stand out. Country leaders in primary care. The Juvoly pattern works best where a single vendor has captured a meaningful share of GP practices in a mid-sized market with its own language and regulatory nuance. Belgium, Portugal, Poland, Austria, Switzerland and the Nordic neighbours outside Sweden all have local scribes with a few hundred to a few thousand practices and limited access to growth capital. These deals are likely to be priced in the low tens of millions of euros, largely in stock, and to close quickly. DACH depth. Germany is the largest healthcare market in Europe and the hardest to penetrate, with its C5 requirements, KBV certification for practice software and fragmented sick fund landscape. Tandem already holds C5, but distribution is another matter. A German scribe with strong practice management integrations, or a nursing-focused player like voize if it were available, would be the single most valuable acquisition Tandem could make. voize's recent $50 million raise makes it expensive, so a smaller Berlin or Munich-based vendor is more probable in the near term. UK clinical specialists and legacy dictation. The NHS is Tandem's largest market and its most contested. Acquiring a UK company with Class IIa clinical decision support or referral automation, in the way Heidi bought AutoMedica, would bolster the operating system story against Heidi's Midlands win. Alternatively, buying an established dictation vendor with acute trust contracts would deliver secondary care distribution Tandem currently lacks. Either move would also reduce reliance on Accurx for UK reach. Adjacent workflow and coding capability. The operating system ambition requires modules beyond the consultation: patient flow, triage, referral management and clinical coding for DRG-based reimbursement. Rather than build all of these, Tandem is likely to acquire small teams with certified products in coding, triage or care coordination, particularly in France, Spain and Italy where its hospital customers are concentrated. Southern and Eastern European roll-ups. Private equity has already identified fragmented southern and eastern markets as buy-and-build territory for healthcare IT. Tandem, with EQT managing its lead investor, has the capital and operating discipline to sweep up a handful of Spanish, Italian and Polish vendors before Doctolib or a US entrant does. The constraint is integration bandwidth rather than money. Each acquired product must be brought onto Tandem's certified platform without breaking the MDR technical file, and each team retained in-country. Juvoly is the proof point; if that integration is visibly successful by year end, the pace of deals will accelerate. 5. What Sellers, Buyers and Investors Should Take from This For founders of European AVT companies, the message is uncomfortable but clear. The window to raise a competitive growth round as an independent scribe is closing, and the value of a company in this segment now depends on three things: certified clinical capability beyond transcription, dominant share in a defined geography or care setting, and clean regulatory and data governance that survives buyer diligence. Companies with those attributes will command strategic premiums from Tandem, Heidi, Doctolib, Microsoft or a US entrant. Companies without them will find that the market has moved on. For hospital groups and national systems, consolidation is broadly good news: a well-capitalised, EU-regulated platform provider gives procurement teams a credible alternative to a US hyper scaler. The risk is lock-in, and buyers should insist on interoperability, data portability and transparent model validation as conditions of any enterprise deal. For investors, the round confirms that European clinical AI is now a late-stage category with a defined leader, a well-funded challenger set and an active M&A market. First-quarter 2026 saw 13 European digital health exits worth $552 million; a growing share of the next wave will be strategic acquisitions by platforms rather than financial buyers. Conclusion Tandem Health's $100 million Series B is the moment the European ambient AI market stopped being a race between dozens of scribes and became a contest between a handful of platforms. The EU's own scale-up fund has picked its champion, the champion has declared its intent to become the operating system for European clinics, and it has already demonstrated the acquisition model it will use to get there. Competitors now face a sharper choice between scale, specialism and sale. The next twelve months will tell us whether Tandem can integrate what it buys as well as it raises, but the direction of travel is set: European healthcare AI is consolidating, and it is consolidating around Stockholm. Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns.www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA#Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk

System C: Potential Acquirers The proposed sale of System C Healthcare by CVC Capital Partners, currently facilitated by the corporate finance advisory firm Arma Partners, marks a defining transaction in the mid-decade consolidation of the United Kingdom’s health and social care technology sectors. The asset, held under the parent entity Asclepius Topco Limited, has undergone a fundamental transformation since its acquisition from Symphony Technology Group in February 2021. At that time, the business was valued at an enterprise value exceeding 20x EV/EBITDA based on a trailing EBITDA of approximately £12 million. By the 2026 fiscal year, System C is projected to deliver an EBITDA of £46 million, reflecting a nearly four-fold increase in profitability under CVC’s stewardship based on a recent Mergermarket report. This trajectory is not merely a result of organic growth but is the culmination of a sophisticated "buy-and-build" strategy that has integrated specialised clinical capabilities in oncology, maternity and medicines management with a dominant market share in the social care and education software verticals. The divestiture process comes at a time when the UK’s National Health Service (NHS) is transitioning from its initial "Frontline Digitisation" phase toward an era of integrated care and "ambient" artificial intelligence. The market for Electronic Patient Records (EPR) has largely matured, with 97% of acute trusts in England expected to have a system in place by March 2026. Consequently, the value proposition for System C has shifted from being a provider of record-keeping software to a strategic data platform that bridges the traditionally siloed environments of acute hospitals and community based social care. This report explores the financial architecture of the transaction, the competitive landscape involving Oracle Health and Epic Systems, the strategic rationale for international expansion via the Australian provider MYP Technologies and the profiling of likely strategic and private equity acquirers in a market defined by high-recurring-revenue SaaS models and AI-driven efficiency mandates. Nelson Advisors research does not constitute investment advice or recommendations in any way. Financial Architecture and Valuation Modelling in the 2026 Exit Environment The financial performance of System C under CVC’s ownership provides a case study in margin expansion through vertical specialisation and technological modernisation. Financial filings for Asclepius Topco Limited show revenues of £107.2 million for the year ending March 31st, 2025. When viewed alongside the projected £46 million EBITDA for FY26, the company exhibits an EBITDA margin approaching 43%, a premium profile that reflects the high scalability of its cloud-native CareFlow and LiquidLogic platforms. The Evolution of Valuation Multiples The 2021 acquisition multiple of 20x EV/EBITDA was considered aggressive at the time, yet it was anchored in the mission-critical nature of the software and the low churn rates inherent in government-funded healthcare contracts. As Arma Partners brings the asset to market in 2026, the valuation will be judged against a higher EBITDA base but within a macroeconomic environment characterised by more disciplined capital allocation and a focus on "profitable efficiency". The resilience of data-driven businesses in the face of generative AI advancements, a trend highlighted by Arma Partners' own research, supports the maintenance of a premium multiple, as these platforms control the primary data sources required for AI implementation. Financial Metric FY2021 (Acquisition) FY2025 (Reported) FY2026 (Projected) Revenue ~£80 million £107.2 million ~£130 million (estimated) EBITDA £12 - £15 million ~£38 million (est.) £46 million (reported by Mergermarket) EBITDA Margin 15% - 18.7% ~35.4% ~35.4% - 43% Implied EV (at 20x) £240 - £300 million N/A £920 million Source: Mergermarket, 23rd Apr 2026, 'System C owner CVC appoints Arma Partners for sale of healthcare software firm' Revenue Quality and Retention Metrics A critical component of the valuation will be the quality of the recurring revenue. In the 2026 market, buyers are increasingly separating software acquisition costs from the total cost of transformation, including data remediation and adoption. System C’s revenue is characterised by: High Recurring Revenue Rate: Estimated at over 90%, consistent with leading peers like The Access Group and Dedalus. Low Customer Churn: Mission-critical EPR and social care systems typically experience churn rates below 2%, as the cost and clinical risk of replacement are prohibitive. Expansion Revenue: The ability to upsell modules such as the "FormFlow AI Assistant" to an existing base of 40 NHS hospitals and 60% of English councils. The integration of MYP Technologies in August 2025 adds an international dimension to the revenue profile. While the absolute revenue contribution of the Australian entity is smaller than the UK core, its role as a beachhead in the APAC region and a provider of 24/7 support capabilities enhances the "global platform" narrative, which typically commands a 2x to 3x turn multiple premium over domestic-only players. Product Ecosystem: Bridging the Acute-Social Care Divide System C’s competitive moat is built upon its "joined-up" digital strategy. While many competitors focus exclusively on the acute hospital environment, System C has built a dominant presence in the "back-office" and community sectors, which are increasingly recognised as the primary bottlenecks for healthcare efficiency. CareFlow: The Clinical and Acute Backbone The CareFlow EPR suite represents a modernized evolution of the legacy Medway system. It encompasses electronic patient records, patient flow management, and clinical communication. In 2026, the focus of CareFlow has shifted toward "ambient" clinical documentation. The acquisition of FormFlow AI has allowed System C to embed AI-driven assistants that help clinicians automate the recording of patient encounters, a move that directly addresses the 98% of social care professionals who identified administrative burden as a primary obstacle to care. The clinical depth of the CareFlow suite is further evidenced by its market leadership in specialised areas: Oncology: Through CIS Oncology, System C manages complex chemotherapy protocols for 80% of the UK market. Maternity: The BadgerNet platform provides a national contract in several regions, including New Zealand, ensuring that the company is deeply embedded in specialised clinical workflows that are difficult for "generalist" EPRs like Epic or Oracle to displace. Medicines Management: Managing over £9 billion in medications annually provides System C with a massive repository of prescribing data, which is a key asset for population health analytics and value-based procurement. Liquidlogic and the Social Care Nexus System C’s acquisition of Liquidlogic in 2009 was a visionary move that anticipated the current drive toward integrated care. Liquidlogic is now the market-leading solution for children’s and adults' social care in England. The strategic relevance of this cannot be overstated: as Integrated Care Systems (ICS) in England seek to manage "bed-blocking" and delayed discharges, the ability to have hospital systems (CareFlow) talk seamlessly to social care systems (Liquidlogic) becomes a "golden ticket" for operational efficiency. International Expansion and the MYP Technologies Acquisition The August 2025 acquisition of Australian peer MYP Technologies serves two primary strategic goals. First, it diversifies the company’s revenue away from the UK’s single-payer risk. Second, it brings specialised community-based and aged care management tech into the portfolio. MYP’s solutions are purpose-built for disability, allied health and aged care sectors that are seeing significant funding increases in Australia ($3 billion commitments) and Europe. Acquisition Target Date Strategic Value Liquidlogic 2009 Established 60% market share in UK social care. OCC 2023 Added integrated contracts and finance solutions for local government. CIS Oncology 2024 Secured 80% of the UK oncology software market. MYP Technologies Aug 2025 Internationalized the platform; added 24/7 global support. The Competitive Landscape: Consolidation and Challenger Dynamics The 2026 UK healthcare IT market is defined by a paradox: while most acute trusts have chosen an EPR, the market remains highly competitive as trusts look for "replacement" systems that offer better interoperability and lower total cost of ownership. The Oracle Health (Cerner) and Epic Dominance Oracle Health (formerly Cerner) remains the market leader in the UK, with approximately 25% of the acute EPR market. However, the company has faced significant headwinds. Oracle’s massive $28.3 billion acquisition of Cerner in 2022 has been followed by reports of financial strain, leading to rumors of a potential divestiture of the unit in 2026 to fund its $156 billion AI infrastructure commitments. Furthermore, Oracle executed significant layoffs on March 31, 2026, cutting an estimated 30% of its Revenue and Health Sciences division. This "talent window" has allowed competitors like System C and Nervecentre to poach experienced EHR specialists and implementation engineers. Epic Systems, by contrast, has seen the biggest gains in market share, rising to 9.7% of the UK market by 2025. Epic’s strategy focuses on "mega-trusts" and regional clusters, such as the £222 million contract for Somerset and Dorset. While Epic dominates the high end of the market, its high implementation costs and "closed ecosystem" perception leave significant room for more agile, cloud-native providers like System C. The Rise of Nervecentre Nervecentre has emerged as the fastest-growing EPR provider in the UK, recently becoming the second-largest supplier by hospital bed count. Nervecentre’s cloud-native platform is being adopted across regional clusters like Liverpool and the East Midlands, emphasising a "shared foundation" for regional transformation. The success of Nervecentre validates the market's appetite for SaaS-based, intuitive tools, a segment where System C’s CareFlow suite is also strongly positioned. Dedalus and the European Deleveraging Dedalus Group, once a dominant force in European health software, has focused on deleveraging and improving profitability in 2025 and 2026. With a market-leading position in DACH and Southern Europe, Dedalus is a formidable peer, but its "no acquisitions" stance through 2026, required to bring leverage down toward 8x EBITDA, effectively removes it as a likely bidder for System C. Strategic Acquirer Profiling: Who Will Buy System C? The "fireside chats" led by Arma Partners are likely engaging a mix of domestic strategic players, US based consolidators and large-scale private equity firms. 1. The Access Group The Access Group is perhaps the most logical strategic acquirer. With a valuation of over £9 billion and a mission focused on "empowering ambitious organisations" through cloud solutions, Access has a proven playbook for rapid M&A integration, having completed over 40 acquisitions in recent years. Strategic Fit: Access is heavily focused on HR, payroll and ERP, but its "Access Care & Clinical" solution for social care is a direct adjacency to System C’s Liquidlogic. The AI Angle: Access is aggressively rolling out its "Access Evo" AI platform. System C’s clinical and social care data would provide the essential training sets for Access to become a dominant AI player in the UK public sector. 2. IRIS Software Group IRIS Software Group has evolved from a specialist in accountancy and payroll into a diversified provider of mission-critical software for the public sector. Strategic Fit: IRIS already manages over 1,000,000 staff globally and pays one in six UK workers. Its specialised "IRIS GP Payroll" and accountancy software for healthcare organisations provide a natural "front-door" into the GP surgeries that must integrate with System C’s hospital and social care records. Consolidation Rationale: Acquiring System C would allow IRIS to bridge the gap between back-office financial management and front-line clinical delivery, creating a "total workforce and care management" platform. 3. Civica Civica is a UK-based public sector specialist that has historically grown through niche acquisitions like InfoFlex. Strategic Fit: Civica’s strength in local government and its existing presence in the health sector make it a natural contender. A merger with System C would create a "UK National Champion" in public service software, providing the scale needed to compete with US hyperscalers. 4. US-Based Hyperscalers and Strategic Bidders (Oracle, Microsoft, Amazon) While less likely to be direct bidders for a UK-centric asset, these firms influence the valuation ceiling: Oracle: If Oracle divests Cerner, it may ironically look to "buy back" into the UK market with a cleaner, more profitable asset like System C once its balance sheet is repaired. Microsoft: Operates as a "neutral infrastructure" layer via Azure and Nuance (DAX Copilot). An acquisition would jeopardise its status as the preferred partner for Epic and Meditech. 5. Private Equity (Thoma Bravo, Francisco Partners, Bain Capital, Hellman & Friedman etc..) Given the current market landscape in April 2026, System C’s reported £46 million EBITDA and its unique position in the UK's Integrated Care Systems (ICS) make it a "platform-grade" asset. While strategic buyers like The Access Group are in the mix, several large-cap US private equity firms have the specific "software + healthcare" mandate required to take over from CVC. Here are the primary US PE contenders: 1. Thoma Bravo Thoma Bravo is arguably the most aggressive US software investor. They specialize in high-margin, mission-critical enterprise software with "sticky" government or public sector contracts. The Play: They recently took Dayforce private for $12.3 billion (late 2025), showing a massive appetite for vertical-specific platforms. Why System C: They prioritise market leaders with high recurring revenue. System C’s dominance in UK social care (Liquidlogic) and its expansion into acute EPRs fit their "buy-and-build" playbook perfectly. They would likely use System C as a hub to acquire smaller European specialized health-tech firms. 2. Francisco Partners Francisco Partners has a dedicated healthcare technology team and a deep history in the UK (having previously owned assets like Zelis and invested in Availity). The Play: They closed a $2.2 billion acquisition of Jamf in late 2025 and have been active in the clinical data space with Avalon Healthcare Solutions. Why System C: Francisco Partners often targets companies at an inflection point. With the NHS pushing for "Federated Data Platforms," they could see System C as the bridge between clinical data and social care data—a high-value intersection for AI-driven health analytics. 3. Bain Capital Bain Capital’s healthcare team is one of the most active in Europe. They have a sophisticated understanding of the "Sponsor-to-Sponsor" (PE-to-PE) market. The Play: They were heavily involved in the 2025 European biopharma and provider surge (e.g., the STADA deal). Why System C: Bain often looks for "complex" integration plays. System C’s multi-pronged approach (hospital, social care, and pharmacy) is complex to manage but provides a massive "moat" against competitors. Bain has the operational resources to help System C expand into other highly regulated markets like Germany or the Nordics. 4. Hellman & Friedman (H&F) H&F typically targets "quality over quantity," preferring a few massive, market-dominating positions. The Play: They are currently investing from their tenth fund ($24bn+) and have a strong preference for software businesses with high barriers to entry. Why System C: If the valuation pushes toward the £1 billion mark (approx. 20-22x EBITDA), H&F is one of the few firms with the "deep pockets" and patience for a long-term hold in the regulated UK healthcare space. While CVC has significantly improved System C's margins (now roughly 35–43%), a US PE firm would likely focus on the "Data Value." In 2026, the value isn't just in the software; it's in the longitudinal patient record that System C controls across both the hospital and the home. System C: Potential Acquirers Market Drivers and Regulatory Headwinds: The 2026 Context The valuation of System C is fundamentally linked to the structural shifts within the NHS and the broader UK regulatory environment. The NHS 10-Year Plan and the "Left Shift" The UK’s health strategy is defined by the "Left Shift", moving care away from expensive hospital settings and into the community and the home. This shift directly benefits System C’s social care and community-focused portfolio (Liquidlogic and MYP). Technologies that facilitate remote patient monitoring (RPM) and community diagnostics are seeing faster adoption than traditional hospital-only tools . Value-Based Procurement and Clinical Validation Starting in early 2026, the NHS has enforced standardized "value-based procurement" guidance. This means that procurement decisions are no longer based on the "cheapest price" but on evidence of long-term patient outcomes and total pathway cost savings. System C’s deep clinical modules in oncology and maternity, which track outcomes over many years, provide the "clinical validation" that generic EPRs lack, making it a more resilient asset in a value-based market. The EHDS and the EU AI Act For international bidders, System C’s compliance with the European Health Data Space (EHDS) and the EU AI Act is a major selling point. The high cost of compliance with these regulations makes it difficult for new entrants to penetrate the European market, thereby increasing the scarcity value of established, compliant platforms like System C. The "EPR" Confusion: Packaging vs. Records A unique contextual factor in the 2026 market is the rollout of the "Extended Producer Responsibility" (EPR) for packaging in the UK. While this is a waste management regulation, it has created a broader demand for "traceability software" across all sectors, including healthcare. Companies like SAP and Workday are integrating these "packaging EPR" modules into their core platforms. A strategic acquirer from the ERP space might view System C as the "missing link" to provide total traceability for medical supplies and patient records in a unified system. Australia and New Zealand: The APAC Strategic Beachhead The acquisition of MYP Technologies is a response to the "Supply Gap" in the global health workforce. By 2030, the global healthcare workforce shortage is predicted to reach 11 million workers. Australia and New Zealand, with their aging populations and high healthcare spend, are key markets for automation technologies. Country Key Public Funding Commitment (2022-2025) Market Opportunity UK ~£9B (2025) for health/social care Integrated care and Frontline Digitisation. Australia ~A$3B (2022) for disability/aged care Community-based care and NDIS support. European Union ~€1.5B (2022) for digital health EHDS compliance and cross-border data. System C's presence in Australia, where it already holds national maternity and child protection contracts, allows it to offer a "global support model". For a US-based acquirer, this provides an immediate, ready-made international expansion vehicle that has already cleared the cultural and regulatory hurdles of the APAC region. Synthesis: The Value Proposition for an Acquirer The sale of System C is not merely the divestiture of a software company; it is the transfer of a strategic infrastructure asset that sits at the center of the UK’s integrated care ambitions. The value proposition for an acquirer is built on three recursive layers of value: Layer 1: The Defensive Core A highly profitable (£46M EBITDA), high-margin (~40%), and low-churn software business with a 90%+ recurring revenue rate. The mission-critical nature of the EPR and social care records ensures that cash flows are protected even in a downturn. Layer 2: The Synergistic Platform The unique "Acute + Social Care" combination. An acquirer like The Access Group or IRIS can leverage System C’s dominance in local government (60% share) to cross-sell a wide range of HR, payroll, and financial software. For an ICS, the "joined-up" record is a primary driver of cost savings, making System C the preferred partner for regional transformation. Layer 3: The AI and International Upside The potential to use System C’s massive, longitudinal data sets (oncology, maternity, medications) to train the next generation of "ambient clinical intelligence". The APAC presence via MYP Technologies provides the "exit ramp" for future growth beyond the UK, justifying a premium multiple in the 18x-22x range. Conclusions and Strategic Outlook Nelson Advisors research does not constitute investment advice or recommendations in any way. As Arma Partners proceeds with the sale of System C, the transaction is expected to be one of the largest in the UK health-tech space in 2026. The projected enterprise value likely sits between £750 million and £900 Million, representing a significant return for CVC Capital Partners on their 2021 investment. The eventual winner of the process will likely be the firm that can best articulate a vision for "Total Integrated Care", one that utilises System C’s data richness to solve the systemic issues of workforce shortages and delayed hospital discharges. While private equity firms remain the most active buyers in the sub-£50m deal bracket, the scale and strategic importance of System C suggest that a large-scale strategic consolidator or a "mega-PE" fund looking for a platform for a global roll-up is the most probable outcome. Ultimately, the System C divestiture reflects a broader trend: in the 2026 health-tech market, the value has shifted from the software to the data and the workflow. The companies that control the clinical and social care record are the ones that will define the efficiency of the healthcare systems of the next decade. System C, with its unique vertical dominance and international footprint, is positioned at the very heart of this transformation. Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns.www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA#Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors: When the Hospital Goes Dark: Why Cybersecurity Is Now a Healthcare Security Priority We tend to think of health security in terms of things we can see under a microscope or feel in a fever. Pandemics, antimicrobial resistance, contaminated water, the next novel virus. These are the threats that governments plan for, that the World Health Organization tracks and that most of us instinctively recognise as matters of life and death. There is a newer threat on that list, and it does not come from a pathogen. It comes from a laptop, often thousands of miles away, operated by someone who has never set foot in a hospital and never will. On 3rd September 2026, the WHO Regional Office for the Eastern Mediterranean, together with the International Telecommunication Union and the United Nations Office on Drugs and Crime, convened 346 people from health ministries, hospitals, emergency services and cybersecurity agencies for a single purpose: to make the case that cyberattacks on health systems are not an IT problem. They are a health emergency, and they should be planned for like one. That framing matters, and this article is about why: what actually happens when a hospital is attacked, why digital transformation has made those attacks more likely and more dangerous, what the evidence says about the human cost and what a sensible response looks like. The quiet dependency Walk into a modern hospital and almost nothing you see runs without software. The receptionist checks you in on an electronic patient record. The nurse scans your wristband before giving you a drug, and the system checks the dose against your allergies. Your blood sample goes into an analyser that talks to a laboratory information system, which talks back to the ward. The radiologist reads your scan on a workstation that pulled the images from a picture archive. The infusion pump beside your bed may be networked. The ambulance that brought you in was dispatched by a computer-aided system, and the paramedic's tablet sent your vital signs ahead before you arrived. None of this is a bad thing. Electronic records reduce prescribing errors. Telemedicine reaches people who could never travel to a specialist. Cloud platforms let a small clinic use tools that once required a data centre. Artificial intelligence is starting to spot tumours on scans and sepsis in vital-sign trends earlier than a tired human can. Digital surveillance is what allowed the world to track COVID-19 in something close to real time. But every one of those systems is also a dependency. The more the care pathway runs through software, the less it can function when the software stops. A hospital's ability to deliver care now rests on the same foundations as a bank's ability to process payments or a utility's ability to keep the lights on. Those foundations can be attacked. What an attack actually looks like The word "cyberattack" conjures images of stolen data and data theft is certainly part of the picture. But the attacks that frighten clinicians most are not the ones that copy information. They are the ones that make it disappear. Ransomware encrypts an organisation's files and systems so they cannot be used, then demands payment for the key. In a hospital, that means the electronic record is gone. The laboratory system is gone. The imaging archive is gone. Staff who have never worked without a screen are suddenly writing on paper, phoning results between departments, and trying to work out which drug a patient was on from a printout that may or may not be current. Operations are cancelled because the anaesthetist cannot see the blood results. Ambulances are diverted to the hospital down the road, which is now dealing with twice its normal emergency load. Consider what happened in London in June 2024. Synnovis, a pathology provider that runs blood testing for several major NHS hospitals in the south-east of the city, was hit by a ransomware group known as Qilin. The blood-testing infrastructure that Guy's and St Thomas', King's College Hospital and their partner trusts relied on stopped working. According to NHS England figures reported by The Record, 10,152 acute outpatient appointments and 1,710 elective procedures were postponed. Because the laboratories could not do rapid blood matching, hospitals fell back on universal-donor blood, and NHS Blood and Transplant had to issue urgent public appeals as national stocks ran low. The disruption did not end after a few weeks. By January 2026, more than 161,000 pathology reports still had not been entered into patient records. South London and Maudsley NHS Foundation Trust recorded 122 patient safety incidents linked to incorrect, unavailable or delayed results, and nearly two years on some of its systems remained unrestored. Almost a million patients had data stolen, including the results of tests for cancer and sexually transmitted infections, and many were not told until late 2025. Then came the finding everyone in health cybersecurity had been dreading. In June 2025, King's College Hospital NHS Foundation Trust confirmed that a patient had died, and that a delayed blood test result caused by the attack was one of "a number of contributing factors" in that death. It was, as far as anyone knows, the first time an NHS patient death had been formally linked to a cyberattack. This is what the WHO means when it says cyberattacks "can disrupt electronic health records, laboratory and diagnostic systems, emergency services and connected medical devices, potentially delaying care and putting patient safety at risk." The sentence is bureaucratic, but the reality behind it is a person who did not get a blood result in time. The largest attack you have probably never heard of If the Synnovis attack shows how a single supplier can knock out care across a city, the Change Healthcare attack in the United States shows what happens when the target is a piece of national infrastructure that almost nobody outside the industry knew existed. Change Healthcare, owned by UnitedHealth Group, is a clearing house. It processes an enormous share of the insurance claims, eligibility checks, prior authorisations and pharmacy transactions that move through the American health system. In February 2024, the ALPHV/BlackCat ransomware group got in and shut it down. UnitedHealth paid a ransom of $22 million in Bitcoin. The operational fallout was extraordinary. Pharmacies could not verify coverage, so patients were turned away or asked to pay in full. Doctors' practices and small hospitals could not submit claims, so money stopped arriving, and some feared they would close. UnitedHealth and the federal Medicare agency set up emergency funding programmes to keep providers afloat. UnitedHealth's own response costs for the year were around $3.1 billion. And in January 2025 the company confirmed that the data of roughly 190 million people had been exposed, the largest health data breach in American history by a wide margin. The lesson here is not primarily about the size of the number. It is about concentration. Health systems have outsourced pieces of their operation to specialist providers, and some of those providers have become so central that their failure is, in effect, the failure of the system. Nobody planned for a single company's outage to disrupt pharmacies from Maine to California, because nobody was looking at the health system as a network with single points of failure. Cyber attackers were. What the evidence says about harm For years, the health cybersecurity conversation ran on anecdotes. Everyone suspected that attacks hurt patients, but the data were thin. That has changed. Researchers at the University of Minnesota School of Public Health, led by health economist Hannah Neprash, examined ransomware attacks on American hospitals between 2016 and 2021 using Medicare claims data. In the first week of an attack, patient volume fell by roughly a fifth, emergency department revenue dropped by around 40 percent, and hospitals delivered less imaging and testing. More importantly, in-hospital mortality among Medicare patients rose from about three per hundred admissions to about four. Across the study period, the researchers estimated that between 42 and 67 Medicare patients died who would otherwise have lived. Those figures exclude anyone with private insurance, so the true toll is higher. A second study, from the University of California San Diego, published in Critical Care Explorations in 2024, looked at something subtler: what happens to the hospitals next door. When a large health system in the region was hit by ransomware, its emergency departments could not take patients, so they went elsewhere. The neighbouring hospitals, which had not been attacked at all, saw a surge in ambulance arrivals, longer waits, more patients leaving without being seen, and an 81 percent increase in cardiac arrests, with worse survival among those patients. An attack on one hospital degrades care across a whole region, in the same way a fire in one building draws every fire engine in the district. This is why the WHO and its partners insist that these incidents be treated as health emergencies rather than "isolated IT problems." The tools that health systems already have for emergencies, from incident command to mutual aid between hospitals to surge planning, are exactly the tools a cyberattack demands. The problem is that in most countries those tools sit in the emergency preparedness directorate, while cybersecurity sits in the IT department, and the two rarely rehearse together. Why healthcare is such an attractive target There are easier targets than hospitals. Why do criminals go after them? The blunt answer is that hospitals pay, and they pay quickly, because the alternative is that people die. A logistics company hit by ransomware can tolerate a week of disruption. A hospital cannot tolerate an hour. That urgency is precisely what a ransomware operator is monetising. Comparitech's analysis of the first half of 2026 counted 410 ransomware attacks on healthcare organisations worldwide, up 14 percent on the previous six months, with median ransom demands of around $300,000 and attacks on healthcare businesses such as pharmaceutical firms and billing companies up 35 percent. Qilin, the group behind Synnovis, remained among the most active. The second reason is that health data is unusually valuable and unusually permanent. A stolen credit card can be cancelled. A stolen medical history cannot. This is why IBM's annual Cost of a Data Breach study has found health care to be the most expensive sector to be breached in for 14 consecutive years, with an average cost of $7.42 million per incident in 2025 and an average of 279 days to identify and contain a breach, roughly five weeks longer than the global average. Attackers are inside health systems for the better part of a year before anyone notices. The third reason is that hospitals are, to put it kindly, easy. Health care is a sector of thin margins, ageing technology and relentless operational pressure. A hospital's IT budget competes directly with nurses and scanners, and it usually loses. The result is a landscape of unpatched systems, shared passwords, remote access tools left over from the pandemic, and thousands of medical devices running operating systems that stopped receiving security updates years ago. The medical device problem That last point deserves its own section, because connected medical devices are the part of the picture that most people, including many clinicians, have never thought about. An MRI scanner, an infusion pump, a patient monitor or a laboratory analyser is a computer with a medical function bolted on. Many run versions of Windows or embedded Linux that are a decade or more old. They cannot simply be patched the way a laptop can, because any software change may require the manufacturer to revalidate the device's safety, and because a scanner that costs a million pounds is expected to last 15 years, not three. So they sit on the hospital network, often with default passwords and open ports, providing a convenient way in and a convenient thing to hold hostage. Regulators have started to act. In the United States, the Food and Drug Administration now has statutory authority under Section 524B of the Federal Food, Drug and Cosmetic Act to require that new "cyber devices" come with a software bill of materials, a plan for managing vulnerabilities after sale, and evidence of a secure development process. The agency's guidance, tightened again in 2025, treats cybersecurity as a patient-safety property of the device rather than an optional extra. As Phil Englert of Health-ISAC put it, cybersecurity engineering "is about preventing devices from doing tasks you don't want or expect." But regulation applies to new devices. The installed base will be there for years. For those, the practical answer is to know what you have, to segment the network so that a compromised infusion pump cannot reach the patient record system, and to monitor for behaviour a device should never exhibit, like a blood-gas analyser trying to connect to a server in another country. Nelson Advisors: When the Hospital Goes Dark: Why Cybersecurity Is Now a Healthcare Security Priority Not just a rich country problem There is a tempting assumption that cyberattacks on health are a problem for wealthy, heavily digitised systems like the NHS or American hospital chains. The WHO's decision to convene its September 2026 webinar in the Eastern Mediterranean region, and the alarm raised by health officials in Liberia a few days later, should put that assumption to rest. Low and middle income countries are digitising health care faster than anyone. Electronic immunisation registries, mobile phone based disease surveillance and cloud hosted patient records are leapfrogging the paper systems that never quite worked. But those systems are acquiring the same dependencies, often with fewer resources to protect them and weaker legal frameworks for pursuing criminals. A ransomware attack on a national HIV treatment database or a vaccine cold-chain monitoring system would be a public health event of the first order, and in many countries there is no plan for it. The WHO's recommendations from the webinar are deliberately practical for that reason. Integrate cybersecurity into national digital health strategies from the outset, rather than bolting it on afterwards. Establish incident response and reporting mechanisms so that an attack on one hospital is known to every other. Run regular simulation exercises, as hospitals do for mass-casualty events. Maintain downtime procedures and paper-based contingencies, so that staff know what to do when the screens go blank. And build partnerships across health, telecommunications, law enforcement and the technology sector, because no ministry of health can fight international organised crime alone. What resilience actually looks like Perfect security is not available. Any hospital that connects to the internet can in principle be attacked, and a determined adversary will eventually get in somewhere. The goal is not to be unbreachable. It is to be resilient: to detect an intrusion quickly, to limit how far it spreads, and, above all, to keep caring for patients while the systems are down. That last point is the one health systems most often neglect. When Synnovis went down, the hospitals that coped best were the ones whose staff had practised working without the lab, knew where the paper request forms were, and had agreed in advance which tests were essential and which could wait. Resilience is a clinical and operational discipline as much as a technical one. It means asking, ward by ward, what happens here if the computers stop for a day, a week, a month, and then rehearsing the answer. Technically, the basics are well understood and depressingly often absent. Multi-factor authentication on every remote access point, so that a stolen password alone is not enough. Offline, tested backups that ransomware cannot reach, so that recovery does not depend on paying. Network segmentation, so that a compromised device or supplier cannot roam freely. An accurate inventory of every device on the network, because you cannot protect what you do not know you have. And a supplier assurance process that asks the pathology company, the software vendor and the cloud host the same hard questions the hospital asks itself, because, as both Synnovis and Change Healthcare showed, the attack that takes down a hospital is increasingly an attack on someone else. Governments are beginning to legislate for this. The United Kingdom's Cyber Security and Resilience Bill, introduced in November 2025 and working its way through Parliament during 2026, tightens obligations on health operators and, crucially, brings their critical suppliers and managed service providers into the regulatory net for the first time. It requires an initial incident report within 24 hours and a full report within 72, backed by penalties of up to £17 million or 4 percent of global turnover. The direction of travel is clear: the supply chain is now part of the health system, and it will be regulated as such. What this means for you If you are a patient, there is little you can do to protect your hospital, and quite a lot you can do to protect yourself. Keep your own record of your medications, allergies and key diagnoses, on paper or on your phone, so that you can tell a clinician what they need to know if their system is down. Be alert to phishing that uses stolen health data as bait, since the criminals who took your details from a breached lab will happily use them to impersonate your GP. And when you are asked to donate blood after an attack, as Londoners were in 2024, understand that the request is not a formality. If you are a clinician, your role is to insist that downtime procedures are real and rehearsed, not a binder on a shelf. You are also the last line of defence against the most common way attackers get in, which remains a convincing email and a hurried click. Be as suspicious of an unexpected attachment as you are of an unexpected drug interaction. If you run a hospital or a health system, the question to ask your board is not "are we secure?" but "what happens to our patients on day three of an outage, and have we tested it?" Cybersecurity belongs on the risk register next to infection control and fire safety, funded accordingly. And if you make policy, the WHO has given you the framing. Treat cyber incidents as health emergencies. Bring the emergency planners and the technologists into the same room. Regulate the supply chain. Fund the basics. And recognise that in a world where health care runs on software, a health system's cyber defences are part of its capacity to keep people alive. The pathogen that isn't one Public health has a long history of learning to see new threats. Cholera was a miasma until John Snow mapped a water pump. Each time, the discipline had to expand its definition of what counts as a threat to health, and each time the expansion felt strange at first. Cybersecurity is the latest such expansion. There is no organism, no vector, no vaccine. But the effect is the same as any other health emergency: care delayed, results lost, patients diverted, and, at the far end of the chain, people dying who did not need to. The evidence for that is no longer anecdotal. It is in the mortality data from Minnesota, the cardiac arrest data from San Diego and a patient safety investigation in south London. The digital transformation of health care will continue, and it should. The question is whether the security of that transformation keeps pace with its ambition. The WHO's September webinar was a statement that it must. The next few years will show whether health systems, and the governments that fund them, were listening. Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns.www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA#Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk

Nelson Advisors: OpenEvidence's Capital Architecture, Clinical Decision Infrastructure and Strategic Outlook Toward 2027 Executive Summary OpenEvidence has established itself as the preeminent artificial intelligence platform in United States clinical practice, commonly referred to across the digital health ecosystem as the "ChatGPT for Doctors". Conceived by serial technologist Daniel Nadler and machine learning researcher Zachary Ziegler, the platform was developed to address an acute structural crisis in modern medicine: the velocity of peer-reviewed biomedical literature, which currently doubles every 73 days, has substantially outpaced the cognitive bandwidth of human practitioners. By coupling a deterministic, citation-linked retrieval engine with a friction-free, Direct to Clinician distribution model, OpenEvidence bypassed traditional enterprise hospital procurement friction. Between early 2025 and mid 2026, OpenEvidence orchestrated one of the fastest capitalisation ramps in enterprise software history. The company scaled its post money valuation from $1 billion to $12 billion in eleven months, ultimately reaching an annualised revenue run rate of $300 million while operating near cash-flow breakeven with gross margins around 90%. As of mid 2026, the application captured active daily usage from more than 40% of all licensed physicians in the United States across more than 10,000 healthcare facilities, processing over 20 million monthly clinical consultations and fielding more than one million point of care queries every 24 hours. Entering the 2027 planning horizon, OpenEvidence is navigating a pivotal strategic transition from an ad-supported, point of care medical search tool into a comprehensive clinical workflow operating system. This expansion encompasses ambient clinical documentation, privacy centric telemedicine communications, hands-free speech to speech interaction, and an agentic multi-model topology termed "medical super-intelligence". Concurrently, the organisation faces substantial operational and regulatory tensions. These include institutional resistance to pharmaceutical advertising, documented performance variance on complex subspecialty diagnostic tasks, escalating competition from foundation model providers and a regulatory landscape that prompted OpenEvidence's complete withdrawal from the European Union and United Kingdom markets under the EU Artificial Intelligence Act. Company Genesis and Architectural Foundations OpenEvidence was conceived in 2021 and formally incorporated in 2022 by Daniel Nadler, a Harvard PhD graduate who previously founded the financial intelligence firm Kensho Technologies (acquired by S&P Global for $700 million) and Zachary Ziegler, a Harvard machine learning researcher. The company accelerated its initial clinical development through the Mayo Clinic Platform Accelerate program before relocating its corporate headquarters from Cambridge, Massachusetts to Miami, Florida in 2025. The architectural premise of OpenEvidence departs fundamentally from standard commercial large language models. While general purpose foundational models rely on probabilistic next-token generation over vast, un-curated web scrapes, yielding variable clinical accuracy and ungrounded hallucinations, OpenEvidence was constructed around a domain specific Retrieval-Augmented Generation (RAG) framework engineered for deterministic citation linking. The platform continuously indexes over 35 million peer reviewed biomedical publications, clinical practice guidelines, and regulatory databases. Crucially, the system architecture enforces an evidentiary cutoff constraint: if indexed peer-reviewed scientific literature is inconclusive or silent regarding a specific clinical query, the engine is programmatically designed to withhold an affirmative claim rather than interpolate speculative conclusions, thereby suppressing ungrounded generative output. To solidify an evidentiary data moat, OpenEvidence entered into direct content licensing and strategic publishing partnerships with leading medical bodies and journals. The platform’s ingestion corpus encompasses full text licensing agreements with the New England Journal of Medicine (NEJM) Group, the Journal of the American Medical Association (JAMA) and its eleven specialty journals (such as JAMA Oncology and JAMA Cardiology), the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines, the American Medical Association (AMA), the American College of Emergency Physicians (ACEP), the American Academy of Family Physicians (AAFP), the Cochrane Library, Nature Portfolio, Wiley, and The Lancet, alongside regulatory monographs from the FDA and CDC. Through these authoritative integrations, the engine provides licensed clinicians with natural language query responses that embed explicit inline citations, allowing practitioners to verify recommendations against primary literature during point-of-care clinical decisions. Capital Architecture and Valuation Progression The capitalisation velocity of OpenEvidence between February 2025 and mid-2026 reflected an aggressive concentration of venture capital into perceived category winners within specialised enterprise AI. The company closed four sequential equity financings in eleven months, doubling or tripling its post money valuation at each raise without experiencing a flat or dilutive interim round. Funding Round Disclosed Date Capital Raised Post-Money Valuation Lead & Key Institutional Investors Seed 2021–2022 Undisclosed (Founder-backed) — Daniel Nadler, Mayo Clinic Platform Accelerate Series A February 2025 $75 million $1.0 billion Sequoia Capital Series B / B-1 July 2025 $210 million $3.5 billion GV (Google Ventures), Kleiner Perkins, Coatue, Conviction, Thrive Capital Series C / C-1 / C-2 October 2025 $200 million $6.0 billion GV, Sequoia Capital, Kleiner Perkins, Thrive Capital, Coatue, BOND, Blackstone, Craft Ventures Series D January 2026 $250 million $12.0 billion Thrive Capital, DST Global, Alkeon, Breyer Capital, Iconiq, Meritech, Nvidia, Mayo Clinic Series D-2 (Tranche) April 2026 $192.5 million $12.19 billion Undisclosed Growth Investors Series E (Contemplated) July 2026 $200 million (Paused) $20.0 billion (Targeted) Institutional discussions paused; explored inbound acquisition inquiries In July 2026, financial reports indicated that OpenEvidence explored an additional $200 million financing round targeting a $20 billion post money valuation. However, executive leadership and the board opted not to finalise the transaction. The rationale for pausing this raise was anchored in the company's operational profile: OpenEvidence achieved cash flow breakeven operations by mid-2026, supported by an annualised revenue run rate that climbed from $150 million in late 2025 to $300 million in July 2026. Generating roughly $25 million in monthly revenue with gross margins near 90%, the business required no external cash injection to fund its computational infrastructure or workforce expansion. Furthermore, founders and existing venture backers resisted unnecessary equity dilution, particularly given that OpenEvidence was actively evaluating preliminary acquisition inquiries from large cap technology corporations seeking vertical AI integration. With total disclosed funding reaching between $735 million and $893 million by mid 2026, OpenEvidence established substantial balance sheet flexibility heading into 2027. Dual Track Commercialisation: Digital Pharma Advertising and Enterprise SaaS OpenEvidence achieved rapid commercial expansion by inverting traditional healthcare enterprise distribution models. Legacy clinical decision platforms, such as Wolters Kluwer’s UpToDate and EBSCO’s DynaMed, built institutional revenue over several decades through multi-year institutional enterprise license negotiations with hospital Chief Information Officers and clinical procurement committees. This approach created high barriers to entry and lengthy sales cycles. OpenEvidence sidestepped this institutional friction through a consumerised, Direct to Clinician (DTC) distribution model, offering its core application entirely free to any practitioner with a verified National Provider Identifier (NPI). The economic engine underpinning this free tier is specialised digital pharmaceutical and medical device advertising. OpenEvidence commercialises the brief multi-second latency interval during which its multi-agent reasoning models query, synthesise and grade clinical evidence. This positioning reaches credentialed prescribers at the point of care when diagnostic and pharmacological decisions are actively formulated. The advertising inventory commands premium pricing compared to general consumer social platforms, which typically realise Cost Per Mille (CPM) rates between $5 and $15. OpenEvidence commands CPMs ranging from $70 to well over $1,000 when addressing highly specialised medical subspecialists such as hematologic oncologists, interventional cardiologists and rheumatologists. This model yields an estimated Average Revenue Per User (ARPU) of approximately $124 across its clinical base. For context, Doximity generates an advertising ARPU of roughly $228 across a broader social networking framework. This inventory allows OpenEvidence to capture digital marketing spend from major life sciences enterprises seeking targeted prescriber touchpoints as traditional field sales detailing declines. Recognising that sole reliance on an ad-supported model creates institutional friction within academic medical centres and integrated delivery networks, OpenEvidence subsequently initiated a secondary commercial channel: a non-ad-supported enterprise software tier. This B2B model mirrors the commercial approach deployed by frontier AI labs such as Anthropic and OpenAI. Under this enterprise framework, health systems pay recurring institutional software license fees to secure ad-free user interfaces, custom hospital formulary and clinical guideline embedding, guaranteed uptime Service Level Agreements (SLAs), and enterprise grade Business Associate Agreements (BAAs) covering protected health information (PHI). This dual-track revenue architecture enables OpenEvidence to leverage free DTC adoption to establish physician daily habit, which then serves as a Trojan horse to close institutional enterprise contracts with hospital leadership. Ecosystem Expansion: Unified Workflow and Communications Suite Throughout late 2025 and 2026, OpenEvidence systematically evolved beyond its origin as a standalone medical search interface, launching modular capabilities designed to capture broader physician workflows. The Visits suite, rolled out initially in August 2025, marked the organization’s entry into ambient clinical documentation. Operating across mobile and desktop interfaces, Visits records patient-clinician clinical encounters and utilises multi-step natural language processing to generate structured clinical notes, including SOAP progress notes and consult summaries. Unlike conventional ambient transcription services that serve strictly as speech to text scribes, Visits integrates the platform's clinical decision support engine directly into documentation synthesis. As clinical entities, such as symptoms, diagnostic hypotheses and proposed medications are discussed, the system cross references them against peer reviewed literature in real time, automatically embedding evidence based guidelines, dosing constraints, and primary citations directly into the assessment and plan sections of the generated note. By mid-2026, Visits had captured more than 37 million minutes of patient encounters. In February 2026, the company introduced the AI Integrated Doctor Dialer, an enterprise clinical communications suite built directly into the OpenEvidence mobile environment. The Dialer addresses physician privacy challenges by allowing clinicians to place voice and video calls to patients from personal mobile devices while displaying institutional hospital or clinic caller ID numbers, thereby improving patient pickup rates while shielding personal contact information. The communications platform incorporates straight to voicemail dispatching, secure bidirectional SMS messaging, and digital in app faxing. The Dialer links directly into Visits, allowing clinicians to convert telemedicine encounters into structured medical notes containing embedded evidentiary citations in a unified workflow. This integration placed OpenEvidence into direct operational competition with Doximity's communications products. To address physical constraints in clinical environments, OpenEvidence introduced Voice Mode in May 2026, deploying a native speech to speech multimodal interface. Designed for physicians in mobile or sterile settings, such as operating rooms, trauma bays, and inpatient rounds, Voice Mode enables clinicians to speak complex medical queries aloud and receive spoken, evidence-backed summaries without interacting with a display. The system synchronises audio output with a written transcript and primary citations on the clinician’s mobile or desktop screen, allowing immediate visual verification upon returning to a workstation. Concurrently, OpenEvidence deployed EvidenceGrade, an analytical tool modelled after Cochrane systematic review standards and the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) framework. EvidenceGrade systematically evaluates, scores, and visualises the methodological strength of the clinical literature supporting each generated response, distinguishing whether an answer derives from randomised controlled trials, systematic meta-analyses, observational studies, or expert consensus. Nelson Advisors: OpenEvidence's Capital Architecture, Clinical Decision Infrastructure and Strategic Outlook Toward 2027 Technical Roadmap Toward 2027: The "Medical Super-Intelligence" Framework During executive presentations at the JPMorgan Healthcare Conference in January 2026, OpenEvidence outlined its core technical roadmap leading into 2027: the development of "medical super-intelligence" powered by a coordinated multi-agent architecture. Daniel Nadler argued that the future of clinical medicine cannot be effectively managed by a single monolithic foundation model. Because modern medical practice is fractured into more than 160 recognised subspecialties, each governed by differing diagnostic heuristics, clinical trial data and pathophysiological models, monolithic LLMs often flatten nuance when evaluating complex multi-morbid patients. To overcome these constraints, OpenEvidence designed a hub and spoke agentic topology modelled after a multidisciplinary hospital care team. At the apex of this architecture sits the Conductor AI, an orchestrating model tasked with clinical intent analysis, token routing and case triage. When presented with a complex patient chart, natural language query, or laboratory panel, the Conductor decomposes the case and delegates sub problems to specialised digital twin models. These specialised models are trained and optimised around discrete clinical domains. such as an oncology agent trained on NCCN protocols and clinical trial outcomes, working alongside cardiology, nephrology and endocrinology agents. In clinical scenarios involving multi morbid patients, the architecture enables inter-agent deliberation. For example, in an oncology patient experiencing immune checkpoint inhibitor induced myocarditis and concurrent renal failure, the oncology agent, cardiology agent and nephrology agent cross examine proposed treatment options, weighing therapeutic benefits against toxicities and contraindications before reaching a synthesised consensus. To prevent the system from encountering quadratic coordination failure, a computational state where open-ended communication between numerous autonomous agents causes severe latency expansion, error compounding, and hallucination loops, OpenEvidence utilises a directed acyclic tree communication structure. Information flows strictly down and back through parent-child node relationships, preserving computational state isolation and ensuring that the final output delivered to the bedside clinician is coherent, deterministically cited, and delivered within point-of-care latency constraints. In September 2026, the company deployed its proprietary model family, named after foundational figures in medical history: William Osler (internal medicine), David Sackett (evidence based medicine), John Snow (epidemiology) and Charles Darwin. The Darwin model serves as the computational engine for advanced clinical reasoning across the platform. Clinical Evaluation Benchmark OpenEvidence Darwin Score Primary Competitor Comparison Scores Clinical Domain & Competency Evaluated MedQA (USMLE) 100.0% Gemini 3.1 Pro (97.4%) / GPT-5.2 (96.8%) Standardised clinical medical licensing examination questions; evaluates fundamental medical knowledge recall. MedXpertQA 72.8% Leading Frontier LLM Ensemble (~70.0–73.0%) Multi-step reasoning across complex specialty and subspecialty medical scenarios. HealthBench Professional 82.7% GPT-5 Series (88.0%) Standardised clinical formulation, safety boundary adherence, and management planning. NOHARM 87.2% Anthropic Claude Opus 4.6 (~84.5%) Clinical safety evaluation measuring the mitigation of non-indicated, contraindicated, or potentially harmful medical orders. Enterprise Electronic Health Record (EHR) Integrations A key strategic objective for OpenEvidence entering 2027 is deep integration within enterprise Electronic Health Record (EHR) environments, primarily Epic Systems. Throughout early to mid-2026, OpenEvidence executed enterprise EHR deployments across three major health systems, transitioning the technology from an unsanctioned shadow-IT lookup tool into an enterprise-sanctioned clinical utility. In February 2026, Sutter Health integrated OpenEvidence directly into its Epic EHR workflows across 24 acute-care hospitals and associated outpatient clinics in Northern California. This deployment was followed in March 2026 by Mount Sinai Health System in New York, which signed OpenEvidence's first comprehensive enterprise B2B deal. The Mount Sinai deployment embedded OpenEvidence directly into Epic across seven hospitals, extending access beyond physicians to registered nurses, clinical nurse specialists, and clinical pharmacists. In May 2026, Cedars-Sinai Medical Center deployed OpenEvidence enterprise-wide within Epic, allowing clinicians to query medical literature with patient-specific chart context, factoring in active diagnoses, lab trends, and current medication lists, directly from the patient record. Integrating within the EHR workflow alters OpenEvidence's operational utility. Historically, third-party medical references required clinicians to switch windows to an external browser tab or mobile app, introducing cognitive friction. By operating as an embedded workspace within Epic, OpenEvidence reduces context-switching during chart review. This technical positioning provides an architectural baseline for bidirectional EHR integration heading into 2027, moving from passive, read-only chart querying toward writing structured clinical notes, evidence-backed diagnostic assessments, and order set justifications directly into patient records via FHIR (Fast Healthcare Interoperability Resources) APIs . Clinical Validation, Diagnostic Boundaries and Regulatory Governance Despite widespread clinician adoption and strong standardized test performance, OpenEvidence’s real-world diagnostic utility and clinical safety profile remain subjects of academic and regulatory scrutiny. A central issue within the clinical informatics community is the divergence between multiple-choice benchmark scores and real-world bedside performance. While OpenEvidence achieved a 100% score on USMLE-style MedQA exams, independent academic trials indicate that performance degrades when evaluated on complex, non-linear subspecialty cases. In a December 2025 pilot study led by Jagarapu et al. evaluating OpenEvidence on the MedXpertQA subspecialty dataset, the standard platform achieved an accuracy of 34% on Quick Consult and 41% on Deep Consult. Furthermore, evaluator-level repeatability, defined as the model producing identical diagnostic outputs when presented with identical clinical prompts over a brief time window, was measured at 77% for Quick Consult and 72% for Deep Consult. This variation highlights the underlying probabilistic behavior of transformer models when processing edge-case medical inputs. Similarly, a prospective pilot study on chronic conditions published in PubMed Central revealed that while OpenEvidence scored highly on clarity (3.55/4.0), relevance (3.75/4.0) and citation support (3.35/4.0), its impact on altering a physician's active management plan scored 1.95/4.0. Investigators concluded that the tool functions primarily as an evidentiary confirmation resource rather than a driver of novel diagnostic strategies. Conversely, in an extensive real-world point-of-care query evaluation (Real-POCQi) published in Nature Medicine by NYU Langone researchers in June 2026, OpenEvidence demonstrated distinct advantages over general frontier models. Graded blindly by 149 board-certified physicians across 30 specialties reviewing 620 actual bedside clinical questions, OpenEvidence outperformed GPT-5.2, Claude Opus 4.6, and Gemini 3.1 Pro by win margins of 25 to 39 percentage points. Evaluators noted that while general models excelled at conversational fluency, OpenEvidence produced higher citation relevance, more accurate dosing guidance, and fewer hallucinations. In the United States, OpenEvidence operates within the non-device carve-out established by Section 520(o)(1)(E) of the Federal Food, Drug, and Cosmetic Act, enacted under the 21st Century Cures Act and refined by the FDA's updated final Clinical Decision Support (CDS) guidance in January 2026. Under this statutory framework, clinical software is exempt from FDA premarket device clearance provided that it satisfies four core criteria: It does not process or interpret medical images, physiological signals, or in vitro diagnostic patterns. It displays, analyzes, or prints clinical literature, guidelines, or patient medical information. It provides contextual recommendations rather than directing a specific diagnosis or therapy. It presents transparent, plain-language clinical logic and verifiable citations that allow the practitioner to independently review the basis of the recommendation, preserving the clinician as the ultimate decision-maker. By maintaining a clinician-in-the-loop framework, OpenEvidence avoids classification as a Software as a Medical Device (SaMD), leaving legal liability for medical decisions with the treating physician. While this regulatory framework supports operations in the United States, diverging international standards led to a significant contraction of OpenEvidence's global footprint. On April 27–28, 2026, OpenEvidence abruptly suspended platform availability and terminated access for all clinicians across the European Union and the United Kingdom. The company cited regulatory uncertainty and compliance exposure under the European Union Artificial Intelligence Act, alongside software device classifications enforced by the European Medicines Agency (EMA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). Under the EU AI Act, AI systems intended to assist with clinical diagnosis or triage risk classification as High-Risk AI Systems, requiring conformity assessments, audit trails of training weights, and legal liability for diagnostic outputs. Rather than re-architecting its models or exposing its capital base to European regulatory enforcement, OpenEvidence chose to withdraw completely from European markets, focusing its resources on the United States. This withdrawal created an opening for localised competitors, such as iatroX in the UK and Heidi Evidence in Europe, which are built around regional clinical guidelines (e.g., NICE, SIGN) and local compliance mandates. Competitive Matrix: Clinical Decision and Workflow Platforms The clinical artificial intelligence sector spans legacy medical reference providers, physician communication networks, ambient documentation startups, and frontier foundational AI labs. Vendor / Platform Primary Value Proposition Commercial Model Evidentiary Grounding Workflow Tooling Depth EHR Integration Status Primary Vulnerability OpenEvidence Multi-agent clinical search, ambient scribing, EHR-embedded evidence Free DTC (Pharma Ads); B2B Enterprise SaaS Deterministic RAG across 35M+ papers (NEJM, JAMA, NCCN) Visits (ambient notes), Doctor Dialer, Voice Mode Embedded inside Epic (Mount Sinai, Sutter, Cedars) EU/UK regulatory withdrawal; subspecialty complexity drop UpToDate Expert AI (Wolters Kluwer) Conversational search over curated, physician-authored reference content B2B/B2C Subscription ($500–$700/year per seat) Human editorial board of 7,400+ physician authors Static reference retrieval, medical calculators Broad legacy EHR integration across global hospitals High subscription cost; slower conversational response times Doximity (DoxGPT / Dialer) Physician professional network, verified dialer, administrative clinical AI Ad-Supported Prescriber Network ($228 ARPU) Broad LLM integration over PubMed and medical data Secure calling, straight-to-voicemail, e-fax, news feed Standalone mobile/web app; limited direct EHR hooks Lacks deep real-time medical literature RAG synthesis Glass Health Integrated encounter CDS, differential diagnosis generator, ambient notes Tiered SaaS ($0 Lite to $200/month Max plan) Peer-reviewed literature, practice guidelines, drug monographs Live encounter drafting, differential diagnosis lists Targeted EHR hooks (Epic, eClinicalWorks, Elation) Smaller clinical reach; fewer exclusive publishing partnerships ChatGPT for Clinicians (OpenAI) General frontier LLM reasoning tuned for medical documentation and lookup Freemium individual tier; B2B Hospital Enterprise Broad pretraining data and general web search RAG Conversational clinical query, note drafting, summarization Enterprise workspace deployments (AdventHealth, HCA) Generalist model prone to hallucination; lacks exclusive medical IP 2027 Strategic Outlook: Capitalisation, Expansion and Structural Risks Heading into 2027, OpenEvidence’s strategic path will be shaped by capital liquidity decisions, enterprise platform expansion, and structural operating risks. Capitalisation and Liquidity Scenarios Operating at cash-flow breakeven with an annualized revenue run rate of $300 million provides OpenEvidence with capital flexibility. The organisation has two primary capitalisation pathways leading into 2027: The Standalone 2027 Initial Public Offering (IPO): With an investor cap table that includes Sequoia Capital, Kleiner Perkins, Thrive Capital, DST Global, BOND Capital, and GV, a public listing represents the standard liquidity path. If OpenEvidence expands its dual-track enterprise B2B contracts alongside its pharmaceutical advertising model to reach between $450 million and $600 million in ARR during 2027, the company could execute an IPO at a targeted valuation between $25 billion and $30 billion, establishing a public benchmark for specialised vertical AI applications. Strategic Mega-Acquisition: Digital health infrastructure continues to draw acquisition interest from hyperscale technology firms seeking clinical domain dominance. Having previously explored inbound acquisition discussions in mid-2026, OpenEvidence represents a strategic target for several major players. Potential acquirers include Microsoft, which could integrate OpenEvidence’s medical search and RAG engine alongside Nuance DAX Copilot and Azure Health; Alphabet, which could combine OpenEvidence’s clinician user base with its internal Med-Gemini models via existing investor GV; or Oracle Health, which could deploy the technology to revitalise its Cerner EHR ecosystem against Epic Systems’ market lead. Operational and Structural Headwinds Despite market leadership, OpenEvidence faces several core strategic risks moving into 2027: 1. Commercial Conflicts of Interest and Advertising Scrutiny Monetising a point-of-care clinical decision support system through pharmaceutical advertising introduces brand and ethical concerns. Clinical ethicists, medical societies and hospital procurement committees have noted the potential conflict of presenting commercial drug advertising alongside algorithmic prescribing and therapeutic recommendations. Even with structural separations between search algorithms and advertising inventory, scrutiny from the Federal Trade Commission (FTC) and FDA regarding commercial influence on physician prescribing remains an ongoing operational vulnerability. Accelerating the adoption of its ad-free institutional enterprise model will be critical to mitigate this exposure within large academic healthcare networks. 2. Electronic Health Record Platform Disintermediation While OpenEvidence achieved EHR integration across Mount Sinai, Sutter Health, and Cedars-Sinai, relying on third-party EHR platforms creates architectural exposure. Epic Systems has integrated generative AI tools natively across its software suite, partnering directly with Microsoft and OpenAI. If major EHR vendors choose to restrict third-party middleware, increase integration fees, or launch native, ad-free evidence-synthesis tools within their core charting interfaces, OpenEvidence could face margin pressure or risk disintermediation from routine bedside workflows. 3. Diagnostic Boundaries and Regulatory Creep The technical transition from passive medical literature retrieval to multi-agent deliberation—orchestrating sub specialist AI agents to analyse complex patient cases, pushes against FDA safe harbor exemptions. Under the 21st Century Cures Act, clinical decision support software risks losing its non-device exemption if it automates diagnostic reasoning, directs specific therapeutic interventions, or obscures algorithmic logic from independent clinician evaluation. As the platform tackles more complex multimorbid clinical presentations, the FDA could conclude that multi-agent deliberation qualifies as Software as a Medical Device (SaMD), subjecting the platform to premarket review, formal clinical validation trials, and ongoing regulatory surveillance. 4. International Market Re entry Barriers By exiting the EU and UK in April 2026, OpenEvidence mitigated immediate regulatory liabilities under the EU AI Act but ceded those markets to regional competitors. Re-entering these regions by 2027 will require re-architecting algorithmic audit systems, completing CE mark medical device assessments, and securing licensing agreements with local clinical guideline authorities (such as NICE, SIGN, and ESMO). A prolonged absence risks allowing regional alternatives to build defensible local switching costs, permanently restricting OpenEvidence's addressable market outside the United States. Strategic Recommendations and Conclusions OpenEvidence has achieved notable distribution efficiency, capturing regular clinical attention across more than 40% of the United States physician workforce. By pairing direct to clinician distribution with deterministic citation linking and targeted pharmaceutical advertising, the company bypassed standard enterprise procurement cycles to build a $300 million ARR business with near cash flow breakeven operations in under five years. However, the operating requirements of 2027 will differ from the platform's initial growth phase. To maintain independence, support a $25 billion to $30 billion valuation, and withstand competition from foundational AI providers and native EHR vendors, OpenEvidence will need to focus on four operational imperatives: Accelerate Enterprise B2B SaaS Transition: The company must actively diversify its revenue base by transitioning from pharmaceutical advertising toward recurring institutional B2B enterprise software contracts, mitigating ethical concerns and locking in health system wide deployments. Advance Toward Bidirectional EHR Write Back: OpenEvidence should expand beyond read-only reference querying, utilising FHIR APIs to enable native, bidirectional EHR documentation and order set drafting that solidifies its workflow position inside systems like Epic. Conduct Prospective Clinical Endpoint Trials: To defend its platform against foundation LLM commoditisation, OpenEvidence should allocate capital toward prospective, peer-reviewed clinical trials demonstrating that platform usage reduces diagnostic turnaround times, curbs medication errors, and improves patient outcomes. Engineer a Compliant International Re entry Strategy: The organisation should develop a modular, localised software architecture capable of satisfying EU AI Act conformity assessments and MHRA device requirements, allowing OpenEvidence to re-enter European healthcare markets and expand its global footprint. By executing across these priorities, OpenEvidence can transition from an ad-supported reference engine into an essential clinical intelligence platform, anchoring the workflow between biomedical literature and bedside clinical delivery through 2027 and beyond. Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns.www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA#Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk

European Digital Health Investment Banking: 10 Key Structural Drivers Accelerating Lower to Mid Market Growth (2026 to 2030 Executive Summary and Macroeconomic Landscape The European digital health and healthcare technology sector is undergoing an institutional realignment. Valued at approximately $96.68 billion in 2025 and projected to expand to $222.22 billion by 2030 at a compound annual growth rate (CAGR) of 18.11%, the market has moved beyond the speculative retail funding cycles that characterised the zero interest rate policy (ZIRP) era. Alongside this software-driven expansion, the broader European medical technology industry maintains an annual asset base of roughly €170 billion with a positive net trade surplus of €5 billion, underscoring the deep industrial foundation upon which digital transformation is taking place. While the initial post-pandemic environment was characterised by a sharp valuation correction and private venture contractions, the market from 2025 onward has stabilised into a disciplined, institutional merger and acquisition (M&A) environment focused heavily on the lower to mid market (LMM). In this domain, corporate entities typically generate between €5 million and €50 million in annual recurring revenue (ARR) and command enterprise values (EV) ranging from €25 million to €250 million. This market maturation is marked by a divergence between deal value and deal volume. European healthcare and life sciences transactions demonstrated resilience through 2025, recording an 87% surge in transaction value to reach €31.8 billion in the first half of the year, even as overall transaction count contracted by 8%. This concentration reflects an institutional flight to quality, wherein strategic acquirers and financial sponsors prioritize proven, defensible assets over early-stage, unproven business models. Private equity buyout capital has emerged as the primary growth engine of this consolidation. Sponsor-backed buyout volume across European healthcare expanded by 276% to €29.6 billion, contributing to an annual buyout total of approximately $59 billion in Europe within an aggregate global healthcare private equity market of $191 billion. Because enterprises in the lower to mid market comprise more than 80% of all corporate operating entities across European digital health, clinical artificial intelligence, Healthcare IT (HCIT), and medical education technology, they represent the primary destination for private equity dry powder and strategic corporate development initiatives. Macroeconomic pressures, structural workforce shortages, and pan-European regulatory codifications have established ten durable structural drivers that are accelerating transaction volume, programmatic rollups, and valuation multiple expansions across this segment through 2030. Sub-Sector Segment EV / Revenue Baseline Multiples (2025–2026) EV / EBITDA Multiples (Profitable Targets) Core Valuation Determinants and Operational Benchmarks AI-Native Clinical & Diagnostic Solutions 6.0x – 8.0x+ 15.0x – 18.0x+ Proprietary clinical training datasets, CE mark certification under EU MDR (Class IIa/IIb), transparent glass-box decision logic, and auditable adherence to the EU AI Act. Reimbursed Digital Therapeutics (DTx) & RPM 5.5x – 7.0x 11.0x – 14.0x Permanent statutory listing status (e.g., German DiGA, French PECAN), demonstrable clinical health economics, and integration into hospital workflows. Core Clinical Infrastructure & EMR Middleware 4.5x – 6.5x 14.0x – 20.0x Net revenue retention (NRR) > 115%, gross margins > 75%, multi-year recurring public hospital contracts, low annual churn (< 4%), and native HL7/FHIR compliance. Medical Workforce Management & Clinical EdTech 4.0x – 6.0x 10.0x – 14.0x Enterprise B2B software contracts, institutional integration with hospital trusts and universities, low clinician onboarding friction, and verifiable staffing cost reductions. Non-Reimbursed Consumer Health & Wellness 1.5x – 3.0x 6.0x – 9.0x High consumer churn rates (> 5% monthly), direct exposure to consumer spending volatility, unverified clinical outcomes, and continuous digital customer acquisition expenditure. 1. Demographic Deficit: The One Million Clinician Shortfall Driving Mission-Critical Automation The primary operational catalyst compelling European healthcare systems to deploy software solutions is a demographic deficit within the clinical labor force. Independent assessments from the World Health Organization (WHO) project a structural shortfall of 940,000 to 1,000,000 healthcare professionals across the European Region by 2030. This supply contraction is compounded by an aging medical establishment, with roughly 40% of practicing doctors across one-third of European nations nearing statutory retirement age, and approximately one in three clinicians currently older than 55. Structural fatigue and bureaucratic strain have exacerbated this dynamic, with one in four European physicians routinely logging more than 50 hours per week, driving between 11% and 34% of the active clinical workforce to consider departing the profession. Constrained by fiscal realities and public expenditure ceilings, European sovereign health systems cannot address this labour supply failure purely through wage increases or cross-border recruitment. Consequently, hospital administrative boards, integrated regional care trusts and private clinic operators are treating software applications as essential labour substituting infrastructure. Capital allocations have shifted toward lower to mid market vendors offering workflow automation, including ambient clinical voice recognition, automated medical coding, algorithmic triage and predictive bed capacity orchestration. These technologies demonstrably liberate 20% to 35% of a clinician’s shift from routine clerical input, directly expanding outpatient throughput and clinical capacity without adding staff. Lower to mid market software vendors addressing these documentation and scheduling burdens command baseline enterprise valuation multiples between 5.5x and 7.5x revenue, reflecting high buyer interest in assets that demonstrate measurable, labour sparing returns on investment. 2. Regulatory Darwinism: The EU AI Act and the Glass-Box Valuation Premium The operational environment for healthcare artificial intelligence in Europe is entering a phase of regulatory stratification. With the European Union Artificial Intelligence Act (EU AI Act) enforcing comprehensive statutory requirements for high-risk systems by August 2026, medical software platforms face rigorous conformity assessments, strict algorithmic quality standards, and continuous post-market surveillance. Concurrently, the European Medical Device Regulation (MDR 2017/745) and In Vitro Diagnostic Regulation (IVDR 2017/746) have reclassified clinical software into higher-risk categories predominantly Class IIa, IIb, and Class III, under Rule 11, requiring notified-body auditing and longitudinal clinical validation. This overlapping regulatory architecture has introduced an institutional filter across the lower to mid market. Unvalidated software wrappers, solutions that query third party, commercial foundation models via generic API endpoints without explainability or underlying IP, face multiple compression or deal abandonment during institutional due diligence. Healthcare procurement authorities cannot deploy unexplainable systems that risk diagnostic hallucinations, data sovereignty violations, or regulatory non-compliance. Conversely, clinically validated, explainable "Glass Box" artificial intelligence platforms, which feature auditable diagnostic pathways, transparent decision logic and verified training on curated clinical cohorts are capturing valuation premiums of up to 35% over legacy peers. Diversified healthcare conglomerates, including Siemens Healthineers, Philips and Medtronic, are actively acquiring mid market European medical AI platforms. By acquiring targets that already possess approved CE marks under MDR and compliant architectures under the EU AI Act, corporate acquirers bypass multi year notified body backlogs and internal development cycles. Regulatory Domain Legislative Mandate & Enforcement Date Technical, Clinical, & Audit Requirements Structural Valuation & M&A Deal Impact High-Risk Medical AI Systems EU AI Act (Regulation EU 2024/1689); statutory enforcement by August 2026. Detailed technical documentation, risk management systems, verified training data governance, logging of algorithmic operations, and human oversight mechanisms. Generic LLM wrappers face valuation compression to 2.0x–3.5x EV/Revenue; compliant "Glass Box" architectures capture up to a 35% valuation premium. Medical Device Software (MDSW) EU MDR 2017/745 & IVDR 2017/746 (Rule 11 Reclassification). Demonstration of clinical efficacy via controlled clinical trials, post-market clinical follow-up (PMCF), and conformity assessments by designated Notified Bodies. Certified targets serve as strategic acquisition shortcuts for multinational acquirers seeking to bypass multi-year notified body bottlenecks. Algorithmic Data Governance EU General Data Protection Regulation (GDPR) and Article 10 of EU AI Act. Strict data minimization, patient consent validation, zero cross-border leakage, and localized bias monitoring across representative clinical cohorts. High enterprise defensibility; strategic acquirers pay premiums (6.0x–8.0x+ revenue) for software with clean, auditable training data provenance. 3. Pan European Scaling Unlocked by the European Health Data Space A major historical factor depressing valuation multiples for European health technology companies relative to their US peers has been market fragmentation. Fragmented national regulatory structures, disparate localised electronic health record (EHR) systems and regional data governance interpretations historically confined early-stage ventures to their domestic markets, preventing them from achieving continental scale. This structural friction is shifting with the enactment of the European Health Data Space (EHDS) under Regulation (EU) 2025/327. The EHDS establishes a unified market architecture for digital health technologies across all 27 EU member states. Between 2025 and 2027, secondary implementing acts are establishing binding technical standards, cybersecurity baselines, and semantic specifications centred on Fast Healthcare Interoperability Resources (FHIR). By 2029, primary use regulations will mandate cross-border interoperability via the European Electronic Health Record Exchange Format (EEHRxF), ensuring that patient summaries, electronic prescriptions, medical images and laboratory reports move across member-state borders. By 2031, the secondary use framework (HealthData@EU) will become operational, granting researchers and health software developers structured, secure access to de-identified longitudinal health data. By replacing fragmented national barriers with unified technical and data-sharing standards, the EHDS expands the total addressable market (TAM) for specialised software from individual domestic markets to a cohesive bloc of over 450 million citizens. Strategic acquirers and financial sponsors are focusing M&A on lower-to-mid market infrastructure platforms that act as connective tissue for this ecosystem. Targets specialising in FHIR-native interoperability middleware, automated pseudonymisation tools and Health Data Access Body (HDAB) integration gateways are securing valuation multiples between 5.5x and 7.0x revenue, as buyers position themselves to capture the upside of unified pan-European health data exchange. EHDS Phase Statutory Timeline Operational Milestones and Regulatory Objectives Lower-to-Mid Market M&A Positioning Phase I: Foundation & Standardization 2025 – 2027 Formulation of technical implementing acts, semantic dictionaries, and cross-border API standards based on FHIR and open protocols. High strategic demand for middleware vendors capable of bridging legacy hospital archives with modern interoperability layers. Phase II: Primary Cross-Border Use Operational by 2029 Mandatory interoperability under the European EHR Exchange Format (EEHRxF); real-time access to patient histories, imaging, and e-prescriptions across all member states. Pure-play vertical SaaS providers can expand cross-border with minimal software re-architecting, supporting broader geographic rollups. Phase III: Secondary Commercial R&D Scaled by 2031 Full operationalisation of HealthData@EU; access to de-identified, longitudinal clinical datasets for research and algorithmic training via Health Data Access Bodies (HDABs). Premium valuations (5.5x–7.0x sales) for platforms controlling organised, clean clinical registries and compliant data-governance tools. 4. Sponsor Buy and Build Playbooks and Institutional Multiple Arbitrage Financial sponsors have structured systematic buy-and-build strategies across European healthcare IT, viewing software as an attractive asset class characterised by recurring subscription revenues, mission-critical workflow stickiness and defensive margins. Backed by significant private equity dry powder, sponsor buyout activity in European healthcare reached record heights through 2025 and 2026, driven by corporate carve-outs, generational founder transitions and cross border rollups. The underlying mechanics of the mid market programmatic rollup rely on multiple arbitrage coupled with operational leverage. A private equity sponsor typically acquires a market-leading regional platform company generating between €15 million and €40 million in ARR and €3 million to €8 million in EBITDA, at an entry multiple of 10.0x to 12.0x EV/EBITDA. Following the initial platform acquisition, the sponsor systematically acquires smaller, fragmented software providers across adjacent geographies or clinical sub-disciplines. These add-on acquisitions (€1 million to €5 million in EBITDA) are typically completed at lower entry multiples of 6.0x to 8.0x EV/EBITDA. Value creation is realised through platform integration: moving disparate, single tenant systems to a shared, multi tenant cloud architecture; centralising administrative, legal, and compliance overhead and cross-selling modular software extensions across the combined customer base. Once the consolidated platform reaches an institutional scale, typically exceeding €15 million to €25 million in combined EBITDA, the sponsor can exit the platform to an upper middle market private equity fund, sovereign wealth manager, or global enterprise buyer at an expanded valuation multiple of 14.0x to 18.0x+ EV/EBITDA. This playbook is demonstrated by specialised software investors like Main Capital Partners, which has executed rollups through platforms such as POLYPOINT for DACH healthcare workforce management, IQ Messenger for clinical messaging in the Benelux region and VideoVisit in the Nordics. Similar consolidation programs are expanding across digital pathology, laboratory information systems (LIS), and specialised radiology workflows. Core Platform Consolidator Financial Sponsor / Backer Regional Platform Asset Target Sub-Sector & Execution Rationale Typical Add-On Valuation Multiples Scaled Exit Multiple Expectation POLYPOINT Main Capital Partners DACH Regional Operations Clinical workforce management, shift scheduling, and institutional hospital resource planning. 6.0x – 8.0x EV/EBITDA 14.0x – 17.0x EV/EBITDA IQ Messenger Main Capital Partners Benelux & Northern Europe Vendor-neutral medical alarms, nurse call communication, and mission-critical event management. 6.5x – 8.5x EV/EBITDA 14.0x – 16.5x EV/EBITDA VideoVisit Main Capital Partners Nordics (Finland, Sweden) Virtual social care delivery, remote consultations, and municipal elderly care automation. 5.5x – 7.5x EV/EBITDA 13.5x – 16.0x EV/EBITDA Specialist Pathology / LIS Rollups Various Middle-Market PE Sponsors Pan European Cross-Border Digital slide scanning management, diagnostic tracking, and automated laboratory middleware. 7.0x – 8.5x EV/EBITDA 15.0x – 18.0x+ EV/EBITDA 5. Post ZIRP Capital Realignment and the Venture-Backed Series B Bottleneck The ending of the zero interest-rate environment has altered the capital structure and late stage funding dynamics of venture backed European digital health companies. Between 2020 and 2022, access to inexpensive growth equity incentivised early stage operators to prioritise aggressive user acquisition and topline growth over near term operational profitability. In the current market, however, late stage venture capital deployment has become selective, creating a capital bottleneck for companies seeking Series B and Series C rounds. A large cohort of digital health companies that secured Series A funding between 2021 and 2023 have exhausted runway extensions and bridge financings. These businesses often struggle to secure new institutional venture capital due to elevated investor criteria: institutional venture funds now require demonstrated unit economics, customer acquisition cost (CAC) payback periods under 18 months, net revenue retention rates exceeding 110% and a clear path toward near term free cash flow generation. This funding dynamic has generated a consistent pipeline of sell side advisory mandates for lower to mid market investment banks. Well capitalised private equity platforms and cash generative corporate incumbents are acquiring venture-backed assets that possess proven technology and regulatory approvals but lack the balance sheet to support standalone commercial scaling. Corporate finance advisors are bridging valuation discrepancies through structured transaction mechanisms, including performance-contingent earn outs, contingent value rights (CVRs), synthetic secondary recapitalisations and rollover equity structures. These mechanisms allow early stage venture investors and founders to secure liquidity while providing upside exposure within a better capitalised operating platform. Historical ZIRP Operating Archetype (2020–2022) Current Disciplined Market Archetype (2026–2030) Core Investment Banking Implication Top-line growth prioritized over unit economics; reliance on unmonetized registered users and non-paying pilot agreements. Operational profitability, positive EBITDA margins and capital-efficient recurring contract expansions. Platforms that fail to demonstrate cash-generative unit economics face multiple compression and liquidity-driven sales processes. Continuous venture funding rounds raised every 12 to 18 months at upward-ratcheting valuation multiples. Tight growth-equity environment; investors require proof of scalable unit economics and sustainable payback periods. An active pipeline of mid-market carve-outs, trade sales and structured rescue consolidations for viable point solutions. Clean, all cash transaction structures executed at elevated revenue multiples (8.0x–15.0x+ ARR). Structured deal terms utilising milestone driven earn-outs, contingent value rights (CVRs), and equity rollovers. M&A advisors structure risk sharing earn-outs tied directly to regulatory milestones, reimbursement listings, and ARR retention hurdles. European Digital Health Investment Banking: 10 Key Structural Drivers Accelerating Lower to Mid Market Growth (2026 to 2030) 6. Hospital CIO Point Solution Fatigue and Core EHR Platform Rationalisation Healthcare provider networks, regional hospital systems, and Chief Information Officers (CIOs) across Europe are actively managing "point-solution fatigue". Over the past decade, clinical procurement teams contracted dozens of disconnected, specialised digital applications to address specific departmental needs, including isolated apps for diabetes tracking, musculoskeletal (MSK) rehabilitation, patient scheduling and clinician shift communication. This uncoordinated software adoption generated significant technical debt, fragmented clinical data across non-interoperable silos, multiplied software licensing expenses and created security vulnerabilities across hospital IT networks. Hospital CIOs and regional healthcare commissioning bodies, such as Integrated Care Systems (ICSs) in the United Kingdom, are actively rationalising vendor rosters. Enterprise procurement policies now prioritise unified, modular clinical suites that integrate directly with the central Electronic Medical Record (EMR) or Hospital Information System (HIS). Single function point solutions face contract termination upon renewal unless they can demonstrate interoperability within broader clinical workflows. This procurement shift is driving two distinct M&A dynamics in the lower to mid market. First, specialised point solutions are executing horizontal mergers, such as combining remote behavioural health tools with cardio-metabolic disease platforms, to offer comprehensive chronic care suites capable of competing for enterprise tenders. Second, pan European HIS incumbents are acquiring targeted software modules to incorporate specialised functionality into their core systems. Major platform consolidators, such as Dedalus Group (backed by Ardian), CompuGroup Medical, and Nexus AG (taken private by TA Associates for €1.21 billion), are systematically acquiring mid market vendors across laboratory software, clinical messaging and patient engagement. These acquisitions allow core EHR providers to protect their competitive position and capture a larger share of hospital IT budgets. Incumbent Core System Consolidator Primary Regional Foothold Capital Architecture & Structural Posture Strategic Focus for Lower-to-Mid Market Bolt-On M&A Nexus AG DACH, Nordics, France Taken private by TA Associates for €1.21B equity value (~€1.22B EV; 19.3x EBITDA). Specialty clinical modules: Laboratory Information Systems (LIS), digital pathology, ambient transcription, and hospital resource planning. Dedalus Group Southern Europe (Italy, France, Spain), DACH, UK Backed by Ardian; Pan-European hospital information system (HIS) market consolidator. Unified patient portals, clinical communication engines, diagnostic decision support tools, and enterprise interoperability layers. CompuGroup Medical (CGM) Pan-European footprint; ambulatory EHR dominance in DACH Subject to institutional private equity interest and take-private evaluations (CVC bid at ~€1.25B EqV). Integrated e-prescribing modules, ambulatory telemedicine platforms, patient communication portals, and billing software. EMIS Group UK primary care infrastructure Acquired by Optum (UnitedHealth Group) for £1.24B EV (21.0x–23.5x EBITDA). Community medicine integration, patient analytics dashboards, and bi-directional integration with the central NHS App infrastructure. 7. Statutory Codification of National Digital Health Reimbursement Pathways A fundamental impediment that historically restricted the enterprise valuations of European digital therapeutics (DTx) was the lack of clear public reimbursement mechanisms. Early stage applications often relied on direct consumer out of pocket payments or private corporate wellness subsidies, resulting in high customer churn and volatile unit economics. The introduction of dedicated national statutory reimbursement frameworks has transformed this landscape, turning accredited digital applications into reimbursable clinical assets that meet institutional underwriting criteria. Germany established the foundation for this framework through the Digital Healthcare Act (DVG) and its Digitale Gesundheitsanwendungen (DiGA) registry, which enables physicians to prescribe approved software applications to over 73 million statutory health insurance beneficiaries. In 2026, the German framework is expanding to cover lower-risk Class IIb medical devices under MDR, expanding the addressable scope of reimbursable digital therapeutics. France followed with its Prise en Charge Anticipée Numérique (PECAN) fast-track framework under Decree No. 2023-232, which provides a one year window of temporary public reimbursement for digital therapeutics and remote monitoring solutions while final clinical utility data is collected. Unlike early iterations of the German framework, the French system incorporates pricing controls, capping digital therapeutic reimbursement at a maximum of €780 per patient annually, while bifurcating remote patient monitoring payments into separate technical fees for software providers and clinical fees for medical teams. Similar value-based statutory pathways have launched or are advancing across Belgium (mHealthBelgium), Austria and the Nordic markets. This statutory codification provides financial sponsors and strategic acquirers with predictable, public-payer backed recurring revenues. The clinical trials and regulatory reviews required to secure permanent listing establish meaningful competitive moats around approved products. Consequently, digital therapeutic and remote monitoring platforms that have achieved permanent statutory reimbursement trade at premium enterprise multiples of 5.5x to 7.0x revenue and 11.0x to 14.0x EBITDA in lower to mid market transactions. In contrast, non reimbursed direct to consumer health applications face valuation discounts, trading between 2.0x and 3.5x revenue due to higher customer acquisition costs and less defensible market positions. National Jurisdiction Statutory Reimbursement Framework & Legal Authority Eligible Medical Device Classification Reimbursement Architecture & Financial Structure Strategic Valuation Multiple Impact Germany DiGA Fast-Track; Federal Institute for Drugs and Medical Devices (BfArM). MDR Class I and Class IIa; broadening to include lower-risk Class IIb starting in 2026. 12-month provisional listing on preliminary evidence; transition to permanent directory listing following proven clinical or structural benefit. Reimbursed platforms command 5.5x–7.0x EV/Revenue and 11.0x–14.0x EV/EBITDA. France PECAN Fast-Track (Decree No. 2023-232); ANS and Haute Autorité de Santé (HAS). MDR Class I, IIa, IIb, and select Class III devices. 12-month non-renewable coverage based on presumption of innovation; structured follow-up applications to permanent LPPR or LATM registries. Valuations match German DiGA levels; strong strategic interest from multinational MedTech consolidators. Belgium mHealthBelgium Validation Pyramid (National Institute for Health & Disability Insurance - RIZIV/INAMI). MDR CE-marked software (Level M1 through M3). Tiered three-level validation process; Level 3 enables full social security integration and physician reimbursement. Assets achieving Level 3 serve as regional expansion platforms for broader Western European market consolidation. 8. Care Decentralisation and the Left Shift Toward Virtual Wards Sustained hospital occupancy rates exceeding 90% across European urban healthcare systems have accelerated policy initiatives to shift care delivery out of acute facilities and into home and community environments. This trend is highlighted in England's 10-Year Health Plan (Fit for the Future), developed following the Darzi Review's operational assessment of the National Health Service. The policy mandates three primary transformations: transitioning from acute hospital settings to community-based care, shifting from reactive illness management to proactive prevention, and modernising analogue workflows into digital-first delivery models. Central to this policy is the expansion of virtual wards and continuous remote patient monitoring (RPM). Under national targets, remote physiological monitoring for cardiovascular and complex respiratory diseases is scheduled to become a standard of care across regional Integrated Care Systems by 2028. This decentralisation requires clinical-grade remote monitoring software, algorithmic early-warning systems and secure communication links to primary care networks. Emerging providers such as Doccla, Luscii and Huma are providing the digital infrastructure that allows hospitals to manage acute and post-operative patients from home, tracking vital signs and automating clinical escalation pathways. In the investment banking landscape, businesses delivering decentralized care infrastructure are in high demand. Strategic acquirers and private equity sponsors are targeting mid-market vendors whose software platforms integrate with medical devices, provide automated clinical triage, and connect with central hospital information systems. Platforms that help healthcare systems reduce hospital readmissions, shorten inpatient length of stay, and avoid physical capital expenditures command premium valuations, positioning them as essential operational infrastructure for European healthcare delivery. Strategic Priority Policy Framework & Healthcare Objectives (2026–2030) Core Digital Health Infrastructure Requirement Lower-to-Mid Market M&A Targets Hospital-to-Community Redistribution England 10-Year Plan / Pan-European Care De-escalation: shifting treatment to community hubs and personal residences. Decentralized EMRs, automated patient intake software, and interoperable remote telemetry platforms. Ambulatory clinical documentation platforms, specialty outpatient suites, and community clinic operations software. Universal Virtual Ward Operationalisation Mandated virtual ward utilisation for cardiovascular, frailty, and chronic respiratory cohorts by 2028. Real-time clinical telemetry dashboards, predictive biometric deterioration algorithms, and continuous IoT integration. Hospital-at-home software platforms, remote biometric tracking tools, and connected medical device integration software. Centralised Digital Access Portals Adoption of universal patient interfaces (e.g., the NHS App) as the front door to public health delivery. Open FHIR APIs, secure identity verification, and bi-directional record exchange systems. Automated triage tools, digital appointment management software, and patient-reported outcome measures (PROMs) platforms. 9. Sovereign IT Mandates, Critical Infrastructure and NIS2 Cybersecurity Compliance The regulatory landscape governing healthcare data security in Europe has made cybersecurity and data sovereignty central to hospital procurement and corporate M&A due diligence. Under Directive (EU) 2022/2555 (the NIS2 Directive), the healthcare sector is designated as essential critical infrastructure, subjecting hospital trusts, healthcare operators and their third party software suppliers to strict digital security standards and rapid incident-reporting mandates. Significantly, Article 20 of the NIS2 Directive establishes direct legal liability for corporate management boards, making C-suite executives personally accountable for institutional cybersecurity non-compliance. At the same time, European public healthcare authorities are emphasising sovereign data architectures to protect patient information from foreign regulatory exposure, including access requests under the US CLOUD Act. In France, strict regulations require platforms managing electronic health data to maintain Hébergeur de Données de Santé (HDS) certification, ensuring that clinical information is processed in secure, authorized facilities. In Germany, the Federal Office for Information Security (BSI) enforces similar data-protection baselines across hospital cloud deployments. These compliance mandates have driven M&A interest in lower-to-mid market vendors specialising in healthcare cybersecurity and Internet of Medical Things (IoMT) security. Hospitals cannot secure complex networks of connected devices, such as diagnostic imaging platforms, physiological monitors and infusion systems, using generic enterprise security software. Consequently, acquirers are purchasing specialised cybersecurity providers that offer automated medical device discovery, continuous vulnerability management, and clinical network segmentation. Vendors that possess verified sovereign hosting architectures and compliant security profiles represent attractive targets for multinational acquirers seeking compliant entry into Continental European healthcare systems. Regulatory Framework Target Entities & Jurisdictional Application Mandatory Cybersecurity Standards Direct M&A and Enterprise Value Implications NIS2 Directive (EU 2022/2555) Healthcare providers, hospital networks, diagnostic centers, and third-party software supply chains. Multi-factor authentication, end-to-end data encryption, automated incident reporting, and continuous cyber risk assessments. Personal C-suite liability under Article 20 accelerates M&A interest in specialized medical device security vendors. French HDS Certification All digital health applications, cloud hosts, and platforms managing French patient health information. Six-tier audit verification covering physical data security, access control, disaster recovery, and sovereign hosting infrastructure. HDS certification serves as a gating criteria for French market entry, supporting valuation premiums for certified assets. German BSI Cloud Security & GDPR German statutory hospital infrastructure and statutory health insurance (GKV) integrations. Implementation of the BSI C5 criteria catalog, zero cross-border data leakage, and technical pseudonymisation. Acquirers require full data-residency verification during financial and technical due diligence processes. 10. AI Native Unit Economics, Workforce Decoupling and Structural Margin Expansion The financial architecture of high-performing European digital health platforms has diverged from older healthcare software business models. Historically, first-generation healthcare IT and technology enabled services companies scaled by expanding headcount in customer onboarding, clinical support and manual data processing. This operational structure capped gross margins at 65% to 75% and limited ARR generated per full-time employee (FTE) to between $200,000 and $400,000. Modern AI-native digital health platforms are decoupling revenue growth from operational headcount expansion. By deploying automated API integrations, synthetic data for model training and automated clinical documentation, these platforms achieve structural operational leverage. Operating Metric Legacy Tech-Enabled Healthcare Services First-Generation Cloud Healthcare SaaS AI-Native Enterprise Digital Health Software ARR Generated per FTE $ / €) $100,000 – $200,000 $200,000 – $400,000 $500,000 – $1,000,000+ Enterprise Gross Margin (%) 40% – 55% 65% – 75% 75% – 85%+ Integration & Implementation Duration 6 – 18 Months 3 – 6 Months 1 – 4 Weeks (Automated FHIR APIs) Annual Net Revenue Retention (NRR) 95% – 105% 105% – 115% 115% – 125%+ Core Operational Benchmark Standard EBITDA Breakeven Focus Standard Cloud Metrics Structurally Meets the Rule of 40 For investment banks, these operational characteristics support more flexible financing structures and faster transaction timelines. AI-native companies can scale from €10 million to €30 million in ARR with minimal incremental hiring, allowing incremental revenue to translate directly into free cash flow. These financial profiles make AI native platforms priority acquisition targets for private equity sponsors and strategic buyers, supporting exit valuations between 15.0x and 18.0x+ EV/EBITDA. Strategic M&A Structuring and Cross-Border Value Creation (2026 to 2030) For investment banking advisory teams and corporate development executives operating in European digital health, executing transactions in the lower to mid market requires structured approaches to deal terms and valuation gaps. Straightforward, all cash transaction structures frequently encounter friction due to differing valuation expectations between founders, early venture investors and disciplined financial buyers. To resolve these pricing disparities, corporate finance advisors are structuring transactions with contingent consideration mechanisms. Milestone driven earn-outs tied to regulatory and commercial milestones, such as securing MDR Class IIb conformity assessments, transitioning from PECAN provisional status to permanent LPPR reimbursement, or achieving cross-border EHR interoperability under EHDS guidelines, allow acquirers to manage risk while providing sellers with pathways to realise their target valuations. Simultaneously, secondary recapitalisations and continuation funds are increasingly utilised to provide liquidity to early venture capital funds with expiring mandates, transferring assets into institutional ownership structures that support multi-year buy and build consolidation. European Region Prevailing M&A Characteristics & Market Dynamics Typical Entry Multiples Regional M&A Strengths & Transaction Catalysts DACH (Germany, Austria, Switzerland) Fragmented market, high transaction volume (~160 healthcare M&A deals annually), and strong statutory frameworks. 6.0x – 13.0x EV/EBITDA; 1.2x – 2.9x EV/Sales. High availability of privately held platform assets; established statutory reimbursement via the German DiGA framework. Nordic Countries (Sweden, Finland, Denmark, Norway) Advanced digital literacy, single-payer systems, and centralized national health databases. 10.0x – 14.0x EV/EBITDA; 4.0x – 6.0x EV/Sales. Predictable software economics, high net revenue retention (> 120%), low annual churn (< 5%), and scalable cloud architectures. United Kingdom Active early-stage capital formation ($4.2B HealthTech funding in 2025), coupled with fragmented procurement. 8.0x – 15.0x EV/EBITDA; 3.8x – 5.3x EV/ARR. The NHS 10-Year Health Plan provides clear policy direction, but commercial procurement is distributed across 42 Integrated Care Systems. Benelux & France Cohesive public-health policies, established national fast-tracks (PECAN), and strict sovereign hosting rules. 7.0x – 12.0x EV/EBITDA; 3.5x – 5.5x EV/Sales. Favourable launchpad for pan-European expansion; structured regulatory fast-tracks support predictable commercial pathways. Investment banks are also taking advantage of geographic arbitrage across European markets. While the United Kingdom remains a major hub for early stage capital formation, its healthcare commercialisation environment is distributed across 42 individual Integrated Care Systems (ICSs), which can lead to prolonged pilot cycles and high customer acquisition costs. Conversely, the DACH and Nordic regions offer established platforms for buy and build strategies. The DACH region provides market scale, a steady supply of founder led businesses, and attractive entry valuations. The Nordic markets feature single payer healthcare models, unified personal identity frameworks, high digital adoption and low customer churn (< 5%), enabling software vendors to consistently deliver Net Revenue Retention rates exceeding 120%. By structuring acquisitions that combine an operational base in the DACH or Nordic regions with international distribution channels, advisors can build scalable pan European platforms positioned for acquisition by multinational corporate buyers or global private equity funds. Conclusion Between 2026 and 2030, lower to mid market European digital health investment banking will be characterised by greater institutional discipline, regulatory convergence, and software consolidation. Macroeconomic demographic realities, highlighted by the impending one million clinician deficit projected by the WHO, have made workflow automation, ambient documentation and clinical triage tools essential operational investments for public and private healthcare providers. Concurrently, the technical and regulatory integration enabled by the European Health Data Space will address the national market fragmentation that historically limited European health technology valuations, creating a unified addressable market of over 450 million citizens. Valuation multiples will remain stratified, with capital flowing disproportionately toward platforms that combine regulatory compliance with demonstrable financial performance. Companies that achieve permanent statutory reimbursement under established pathways such as DiGA and PECAN, maintain certified compliance under the EU AI Act and MDR, adhere to NIS2 cybersecurity standards and generate high ARR per employee will command premium valuations (14.0x to 18.0x+ EV/EBITDA and 6.0x to 8.0x+ EV/Revenue). For investment banks, financial sponsors and corporate development leaders, navigating this market will require executing programmatic buy and build strategies, bridging valuation spreads through structured earn outs, utilising geographic arbitrage across DACH and Nordic platforms and consolidating specialised point solutions into integrated enterprise clinical suites. Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns.www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA#Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk

Activity across European HealthTech this week centred on remote patient monitoring, clinical AI infrastructure, and EU-backed commercial rollouts: Implicity secures €35M to expand cardiac AI monitoring: French healthtech startup Implicity announced a €35 million growth round led by IRIS. The company’s SaMD (Software as a Medical Device) platform aggregates and normalizes telemetry data from cardiac implantable electronic devices (CIEDs) across major hardware manufacturers. The capital will fund international expansion—particularly into the US—and further train proprietary predictive algorithms for heart failure exacerbations. Check Point Care accelerates European hospital pilots: Bulgarian remote monitoring developer Check Point Care secured hospital pilot agreements and crossed 10,000 pending orders for its AI-integrated patient monitoring wearables. The scaling milestone was facilitated via the European Innovation Council (EIC) Accelerator matchmaking and trade framework. Institutional push for domain-specific clinical models: Procurement trends across UK, German, and Nordic health networks continue tilting toward specialised, vertical medical models over generalised LLMs. Clinical validation data released by Danish healthcare AI company Corti underscored this shift, showing specialised diagnostic and administrative coding engines outperforming broader foundation models in hospital electronic health record (EHR) environments. Regulatory sandboxing under the EU AI Act: European MedTech trade bodies and health regulators intensified alignment on regulatory sandboxes. Following the recent enforcement milestones of the EU AI Act, these sandboxes are being coordinated alongside Medical Devices Regulation (MDR) transition paths to give clinical software and diagnostic startups a pathway to validate models in live environments without duplicative compliance delays. Activity across European Health AI this week centred around digital twins, Neuro AI and guidelines for the use of AI across the NHS EIC launches pilot cohort for clinical digital twins and physical AI: The European Innovation Council (EIC) announced the first 20 selected projects under its Advanced Innovation Challenges pilot. The cohort includes computational digital twins for stroke intervention and tumor-on-chip diagnostic models. Each team receives €300,000 for initial benchmarking, with up to €2.5 million available for stage-two clinical validation. EU advisory body issues policy statement on Neuro AI governance: The European Group on Ethics in Science and New Technologies (EGE) called on EU regulators to establish dedicated governance frameworks for neuro AI. The statement urges specific legal protections for neural data inferences, oversight over emerging "Brain Foundation Models," and an assessment of how existing EU AI Act mandates apply to invasive and non-invasive neural interfaces. UK MHRA advances transparency guidelines for NHS clinical AI: Britain's Medicines and Healthcare products Regulatory Agency (MHRA) issued targeted guidance and recommendations for artificial intelligence used in healthcare settings. The recommendations focus on clinical transparency, algorithmic accountability, and medical device classification to streamline safety assessments as AI triage and diagnostics scale across NHS trusts. Implicity secures €35M on cardiac AI outcomes: French medical software provider Implicity raised €35 million to scale its cardiac remote-monitoring algorithms into international hospital networks. The company published clinical data linking its predictive heart failure telemetry to a 26% reduction in patient mortality, signalling heightened investor interest in AI platforms with peer-reviewed survival and workflow data. Activity across European MedTech this week centred on implants, preventative imaging, regulation and rehabilitation. Xeltis secures €20.5M for restorative cardiovascular implants: Dutch clinical-stage MedTech company Xeltis closed a €20.5 million financing round. The funding will advance late-stage clinical trials for its bioabsorbable polymer implants, which enable endogenous tissue restoration—allowing the patient's body to naturally rebuild heart valves and blood vessels before the synthetic matrix safely dissolves. Onalabs closes €9.3M Series A for sweat-sensing biowearables: Spanish hardware developer Onalabs raised €9.3 million to commercialise its medical-grade, non-invasive skin patch. The wearable continuously analyzes sweat biomarkers (including lactate, glucose, and electrolytes) to monitor chronic heart failure and remote intensive care patients, feeding data directly into hospital telemetry workflows. Ahead Health raises €8.7M for preventative imaging rollout: Swiss diagnostics company Ahead Health completed an €8.7 million round to expand its preventative MRI screening centers across Germany and the Netherlands. The platform couples rapid whole-body magnetic resonance imaging with proprietary image analysis protocols for early detection of asymptomatic oncological and cardiovascular abnormalities. Strolll secures €5M for AR-driven neuro-rehabilitation: UK MedTech firm Strolll raised a combined €5 million in venture funding and Innovate UK grants. The startup develops software running on commercial augmented reality headsets that projects visual and auditory cues to treat gait freeze and motor impairment in patients with Parkinson's and stroke-related neurological conditions. MedTech Europe mobilises around EU Safe Hearts diagnostic initiative: Industry association MedTech Europe initiated member rollout campaigns for the upcoming EU Screening Week. The program aims to accelerate standard-of-care adoption for point-of-care in vitro diagnostics (IVDs) and early cardiovascular risk screening across EU health systems, targeting early biomarker detection for diabetes and arterial disease. Regulatory alignment on MDR and AI Act dual conformity: European notified bodies and legal working groups clarified conformity timelines under the EU Digital Omnibus frameworks. While baseline transparency mandates for algorithmic tools are active, dual MDR/IVDR high-risk compliance tracks were structured to avoid immediate notified-body bottlenecks, giving hardware-software hybrid device manufacturers runway through late 2027. Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns.www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA#Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk

Nelson Advisors: Killer features Apple could build into Apple Health to compete with WHOOP and Oura What Apple's health roadmap could look like over the next two years, the killer features it could build into Apple Health, the partnerships to watch, and the medical specialties it is most likely to target. On the 9th of September 2026 Apple unveiled the Apple Watch Series 12 and Ultra 4 alongside a redesigned Health app and for the first time the company said the quiet part out loud. Alongside a new "Health Sensing System" that samples heart rate every five seconds and HRV every five minutes, Apple introduced a 0–10 Readiness score, a Health Age metric inside a new Longevity tab, an Apple Intelligence driven Insights tab, and in app blood testing through Quest Diagnostics at $119 for more than 50 biomarkers. Readiness, Health Age and lab panels are not features Apple invented. They are the three pillars that WHOOP and Oura have spent the last five years building their businesses on. The timing is not accidental. WHOOP closed a $575 million Series G at a $10.1 billion valuation in March, with Abbott and the Mayo Clinic on the cap table and a stated intention to make that its last private round. Oura filed for a Nasdaq IPO in early September targeting a valuation north of $16 billion, on the back of $1.4 billion in trailing revenue growing 74% year on year, five million paying members and a 94% hardware-to-subscription conversion rate. Both companies have proven that consumers will pay a recurring fee for interpreted biometrics. Apple, which has never charged a penny for Apple Health, has now watched two upstarts build a combined $26 billion of enterprise value on top of a business model it chose not to pursue. So is Apple coming for WHOOP and Oura? The short answer is yes, but not in the way most commentators expect. Apple is unlikely to try to out-WHOOP WHOOP. It is far more likely to reframe the category so that recovery scores become a commodity feature of the platform and the real battleground shifts to something only Apple can do at scale: turning a billion-plus devices into a clinically credible, longitudinal health record with a services layer on top. We set out what that could look like between now and autumn 2028. Where Apple actually stands today It is worth being precise about Apple's starting position, because it is stronger and weaker than it looks. On hardware, Apple is well ahead. The Series 11 in September 2025 brought FDA cleared hypertension notifications, a Sleep Score and heart-rate sensing in the AirPods Pro 3. Series 12 adds a new LED array with better skin contact and the 60x increase in heart rate sampling that underpins Readiness. Apple already has FDA cleared ECG, irregular rhythm notifications, sleep apnoea notifications, hearing aid functionality in AirPods and a hypertension algorithm developed on data from more than 100,000 participants. No other consumer wearable company comes close to that regulatory portfolio. On software and services, Apple has been behind, and it knows it. The much-rumoured "Health+" AI coach, code named Project Mulberry, was scaled back in February 2026 after Eddy Cue took over the health division following Jeff Williams' retirement. Bloomberg's reporting was blunt: Cue concluded that WHOOP and Oura were shipping "more compelling and useful features" and that Apple's plan "didn't meet that bar". Rather than a big-bang subscription launch, Mulberry's components are now arriving piecemeal. The Insights tab, Readiness, Health Age and the camera based fitness assessment in the redesigned Health app are the first tranche. The AI health chatbot, walking pattern analysis and health-aware Siri are still to come. That reorganisation matters for the two year outlook. Apple's health division is now run by its services chief, whose remit is recurring revenue, not by its operations chief. The strategic question inside Apple is no longer whether health should be a services business; it is how and when. The next two years: a plausible Apple roadmap Nobody outside Cupertino has the roadmap, but Apple's cadence is predictable enough to sketch a credible one. Here is what we think the next four release cycles could look like. Autumn 2026 (now): the catch-up release. Series 12 and iOS 27 close the feature gap on Readiness, Health Age and labs. The redesigned Health app launches in US English only later this year, which tells you Apple is still tuning the Apple Intelligence layer. Expect the AI chatbot for wellness questions to arrive in a point release over winter, and expect Apple to spend the next six months quietly measuring how many users actually open the Insights tab every day. That engagement number will decide everything that follows. Spring 2027: the services test. Once Apple has daily-active data on Insights and Readiness, the logical next step is a paid tier. We think Apple is more likely to fold health into Apple One and Fitness+ than to launch a standalone Health+ at first, using Fitness+ as the wrapper for personalised training plans driven by Readiness and Health Age. The Quest lab panel is the first explicit health transaction inside the Health app, and it establishes a commerce rail Apple can extend to repeat testing, specialist panels and eventually prescription services. Autumn 2027: the sensor release. Reports point to blood-pressure sensing hardware being explored for the Ultra line and to a leadership change on the non-invasive glucose project, with Zongjian Chen taking over in May 2026 in what Bloomberg framed as a sign the work is "finally progressing". Optical glucose remains years away, but a cuffless blood-pressure estimate, sitting alongside the already-cleared hypertension notification, is the feature most likely to ship in 2027. The Ultra 4's two-day battery is the other tell: Apple needs multi-day wear for overnight vitals, which is exactly where Oura's ring wins today. Spring to autumn 2028: the form-factor question. The "iRing" rumour resurfaced in June 2026 via prototype collector Kosutami, and Bloomberg has hinted at a "subtle" health and control wearable. We are sceptical of an Apple ring in this window, because it would cannibalise the Watch, but a low-cost, sensor-only band or a health-focused AirPods product that captures overnight vitals is plausible. Apple's real answer to the ring is not another ring. It is spreading sensing across Watch, AirPods and iPhone camera so that the data set is complete regardless of which devices you wear to bed. Killer features Apple could build into Apple Health The features that would actually hurt WHOOP and Oura are not the ones that copy them. They are the ones that exploit assets neither company has. A longitudinal, clinically legible health record. Apple Health already ingests medical records from thousands of providers in the US and UK, medications, lab results, immunisations and every sensor stream from Watch and AirPods. If Apple Intelligence can synthesise that into a single narrative, a Health Age that is informed by your actual LDL, HbA1c and blood pressure trend rather than just your HRV, it becomes something WHOOP Age and Oura's Cardiovascular Age cannot match. WHOOP has partnered with HealthEx for EHR syncing precisely because it lacks this; Apple has had it since 2018. Readiness with medical context. WHOOP's and Oura's recovery scores are elegant but blind to clinical state. Apple can annotate Readiness with the fact that you started a beta blocker last week, that your hypertension notification fired, or that your latest Quest panel showed low ferritin. Readiness that explains why you are not recovering, using medication and lab data, is a categorically different product from readiness that tells you your HRV is down. Passive screening at population scale. Apple's strongest muscle is turning a validation study into an FDA-cleared notification and pushing it to hundreds of millions of wrists overnight. Hypertension, atrial fibrillation and sleep apnoea are done. The next candidates are already visible in the Apple Health Study launched with Brigham and Women's in February 2025: gait and fall-risk from iPhone motion, cognitive decline from typing and speech patterns, early respiratory infection from overnight vitals and hearing loss progression from AirPods. Each one is a feature WHOOP or Oura could build; none is a feature they could get cleared and deployed at Apple's scale. Camera as sensor. The new fitness assessment that uses the iPhone camera to estimate VO2 max, flexibility, strength and balance is the first glimpse of what may become Apple's most underrated health input. Visual Intelligence nutrition scoring, mole and skin tracking, wound monitoring, posture and movement analysis are all within reach of the phone in your pocket, and none of them need a ring. A women's health platform, not just cycle tracking. iOS 27 adds perimenopause and menopause detection with notifications for users over 40. WHOOP's female membership grew 150% year on year and Oura's core demographic skews female; both have leaned into pregnancy, fertility and hormonal insights. Apple's advantage is the ability to link cycle data to temperature from Watch, sleep from AirPods, labs from Quest and clinician records from Health Records, then hand it to a Fitness+ programme built for that life stage. This is a segment where Apple has historically under invested and where the upside is large. Care coordination and the "Health Wallet". Apple Wallet already holds insurance cards in the US. A Health app that can book the lab, hold the result, share it with your GP via Health Records, surface it in a Siri conversation and flag it in Readiness is a care navigation layer, not a wellness app. That is the feature that would make a WHOOP or Oura subscription feel narrow by comparison. Partnerships to expect Apple does not acquire its way into categories; it partners, learns and then internalises. The Quest deal is the template and it is worth reading closely because WHOOP signed the same partner a year earlier for its 65-biomarker Advanced Labs. Apple matched the price point and the location footprint. Here is where we expect the next deals. Diagnostics and continuous glucose. Oura's integration with Dexcom's Stelo over-the-counter CGM, and Dexcom's equity investment in Oura, gave the ring a metabolic story before Apple had one. Until Apple's optical glucose project matures, the fastest route to metabolic health is a first-party integration with Dexcom or Abbott's Libre, surfacing glucose curves in Insights and correlating them with meals captured by Visual Intelligence. Abbott's decision to invest in WHOOP's Series G suggests the CGM makers are hedging; Apple has the leverage to demand a deeper integration than either rival can. Pharma and clinical research. Apple's first pharma study was with GSK, and the Apple Health Study is designed as a permanent research platform. Expect Apple to formalise a research partner programme for pharma sponsors who want decentralised trials running on Watch and iPhone, particularly in cardiometabolic disease, sleep and neurology. This is a revenue line WHOOP and Oura cannot access at scale, and it feeds the validation data Apple needs for the next round of FDA clearances. Health systems and payers. In the US, the obvious partners are the large integrated systems that already support Health Records, plus Medicare Advantage plans looking to subsidise devices for hypertension and atrial fibrillation management. In the UK, the NHS App and the Federated Data Platform are the integration points, and an Apple hypertension or sleep-apnoea pathway that feeds directly into primary care triage would be a genuine differentiator for the UK market. The commercial model here is a per-member subsidy paid by the payer rather than the consumer, which neatly sidesteps Apple's reluctance to charge for Health. Telehealth and clinician access. WHOOP's on-demand clinician video consultations, announced in May 2026, are its bid to close the loop from insight to action. Apple is unlikely to employ clinicians, but it will need a fulfilment partner if Insights is going to recommend follow-up. Whether that is a telehealth network, a retail pharmacy chain or a direct link to the user's own provider via Health Records is one of the more interesting strategic choices of the next two years. Employers and insurers outside the US. Oura counts the US Department of Defense among its largest enterprise customers. WHOOP has built an enterprise channel with sports teams and employers. Apple has largely left this segment to partners such as Vitality, but a Health Age metric that employers and insurers can incentivise against is the kind of feature that makes an enterprise programme worth building. Medical specialties Apple is most likely to target Apple's pattern is to pick conditions that are common, under-diagnosed, detectable from passive optical or motion data, and have a clear clinical pathway when flagged. On that basis, the next two years are likely to concentrate on five areas. Cardiology and cardiometabolic disease remains the centre of gravity. Hypertension notification is live; cuffless blood-pressure estimation and better arrhythmia detection are the natural extensions, and the sub-five-second heart-rate sampling in Series 12 is effectively a platform for both. Heart-failure decompensation monitoring, using resting heart rate, respiratory rate and overnight SpO2, is the high-value clinical use case that sits just beyond. Sleep medicine is the specialty where Oura is strongest and where Apple has been weakest, because the Watch is uncomfortable to wear overnight and needs charging. Sleep apnoea notifications and the Sleep Score changed that. The Ultra 4 battery, AirPods-based overnight sensing and a Readiness score that depends on sleep quality all point to Apple treating sleep as a primary battleground rather than an afterthought. Metabolic health and endocrinology, particularly prediabetes and weight management, is the fastest-growing consumer health category in the world thanks to GLP-1 medications. Oura already tracks GLP-1 use and syncs CGM data; WHOOP has weight-management features. Apple's Visual Intelligence nutrition scoring and the Quest metabolic panel are the opening moves. A GLP-1 companion experience — dosing reminders, side-effect tracking, muscle-preservation training plans via Fitness+ — would be an obvious and lucrative addition. Women's health and menopause is under-served and under-monetised across the whole industry. The iOS 27 perimenopause features, combined with Watch temperature sensing and the labs rail, give Apple the ingredients for a proper mid-life women's health programme, and Fitness+ already has content built for it. Neurology and healthy ageing is the long-term play. Health Age and the Longevity tab are consumer framing for what is really a healthy-ageing platform. Gait analysis, fall detection and prediction, cognitive screening from device interaction, and hearing health from AirPods together form the basis of a proposition for the over-60s that neither WHOOP, with its athlete heritage, nor Oura is positioned to deliver. This is also the demographic with the highest healthcare spend and the strongest willingness to pay. Mental health is the notable omission. Apple has a State of Mind logging feature and has studied depression screening, but has been cautious about clinical claims. We would expect mood and stress insights to arrive inside the Insights tab rather than as a standalone specialty. Nelson Advisors: Killer features Apple could build into Apple Health to compete with WHOOP and Oura What this means for WHOOP and Oura It would be easy to conclude that Apple's move spells trouble for both. The reality is more nuanced, and the two companies face different risks. WHOOP is the more exposed. Its differentiation has been the recovery score, the coaching layer and, more recently, medical-grade features like the FDA-cleared ECG and blood-pressure insights on the WHOOP MG. Apple now has a Readiness score, a deeper regulatory portfolio, and the same lab partner at the same price. WHOOP's year-long dispute with the FDA over its blood-pressure feature, only resolved when the agency changed its wellness guidance in January and closed the warning letter in June, is a reminder that the medical-grade positioning cuts both ways. WHOOP's counter is its screenless, always-on form factor, its athlete community, its rapidly growing female membership and the on-demand clinician layer. Its $1.1 billion bookings run rate at 103% growth is real, but a public-market investor will now price in Apple as a direct competitor rather than a complementary platform. Oura is better insulated, for three reasons. First, the ring form factor is a genuine preference for a large segment who will not sleep in a watch, and Apple's answer to that is at least two years away. Second, Oura has 76% of the smart-ring market and a partnership strategy — Dexcom, Carrot Fertility, the Department of Defense, and integrations with Apple Health itself — that makes it a data source for the Apple ecosystem rather than an enemy of it. Third, its 94% subscription conversion and 55% gross margin give it the economics to keep investing in software. Oura's risk is different: if Apple makes Readiness, Health Age and sleep insights free on a $399 Watch, the willingness to pay $5.99 a month for a ring that does the same things gets tested, and the IPO valuation assumes it holds. The wider read-across for healthtech founders and investors is the one we see most often at Nelson Advisors. When a platform owner enters a category, the companies that survive are the ones with a proprietary sensing modality, a clinical or enterprise distribution channel the platform cannot easily replicate, or a form factor the platform chooses not to build. Feature parity is not a moat. WHOOP and Oura both know this, which is why one is racing towards clinical services and the other towards an IPO before the Series 12 lands on wrists on 18 September. Conclusion Apple is coming for the category WHOOP and Oura built, but it is doing so on its own terms. The next two years will see Apple commoditise recovery scores, longevity metrics and lab testing as free features of the Health app, then build a services and partnership layer above them that draws on assets no rival has: a billion sensors, an FDA clearance machine, Health Records, Apple Intelligence and a services chief who now runs health. Cardiology, sleep, metabolic health, women's health and healthy ageing are the specialties where that layer will show up first. For WHOOP the question is whether medical-grade positioning and clinician access are enough to justify a premium subscription against a free Apple equivalent. For Oura the question is whether the ring remains a preference or becomes a niche. For everyone else in digital health, the question is the one we always come back to: when Apple decides your feature is a platform feature, do you build, buy, partner or sell? Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns.www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA#Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk

Nelson Advisors: HealthTech 2027 and the Big Move From Software to Hardware to De-Risk the AI Threat and address the Defendability questions For fifteen years the smartest money in HealthTech had a simple thesis. Software eats the world, healthcare is the biggest and slowest-moving industry on earth, and so the biggest returns would come from software companies that digitised, automated and re-platformed the way care is delivered, paid for and administered. Asset-light, high gross margin, infinitely scalable and defended by data, workflow lock-in and the sheer difficulty of selling into hospitals and payers. That thesis is now under real pressure and the pressure is coming from the very technology that was supposed to be its next chapter. Generative AI has made software cheaper to build, faster to copy and harder to defend than at any point since the cloud era began. The question every board, every investment committee and every founder in HealthTech is now asking is the same one: what, exactly, is our moat when a foundation model can generate our product? This post argues that one of the most important answers to that question in 2027 will be physical. We expect a visible shift in both investor appetite and founder ambition towards HealthTech companies that build hardware, or that own a hardware layer as part of a full-stack proposition. Not because hardware is easy, but precisely because it is hard and because hardness is what defensibility looks like in a world where software has become abundant. The AI threat to HealthTech software is real and it is not theoretical It is worth being precise about what the threat is, because it is easy to overstate in either direction. The first-order threat is to the cost of building software. Tools that write, test and ship code have compressed the time and headcount needed to produce a credible application from years and dozens of engineers to months and a handful. A HealthTech SaaS product that took a Series A to build in 2019 can be prototyped by a small team in a fraction of the time today. That is wonderful for founders and terrible for anyone whose valuation rested on the assumption that their product was hard to replicate. The second-order threat is to the application layer itself. The large model providers and the hyperscalers are no longer content to sell tokens; they are moving up the stack into vertical workflows, including clinical documentation, prior authorisation, revenue cycle, patient communication, coding and triage. When a general-purpose model with a well-designed agent framework can perform the task that a point-solution SaaS company was built to perform, the SaaS company's software becomes a thin wrapper, and thin wrappers do not command venture multiples. The early-2026 sell-off in public software stocks, triggered in part by exactly this fear, was a warning shot that private-market HealthTech investors have not forgotten. The third-order threat is to the traditional software moats. Proprietary data is less defensible when models can be trained or fine-tuned on synthetic and public data to comparable performance. Workflow integration is less defensible when agents can operate across systems that were never designed to talk to each other. Network effects are less defensible when the switching cost of moving from one AI-native tool to another is low. Even the most cherished HealthTech moat, the difficulty of selling into the NHS or a US health system, is being eroded as buyers consolidate onto a small number of platforms and as the incumbents in electronic health records ship their own AI features into an installed base that already trusts them. None of this means HealthTech software is dead. It means that the average HealthTech software company is more exposed than it was, that the gap between the winners and everyone else will widen, and that "we have an AI feature" has stopped being a differentiator and become table stakes. For investors trying to underwrite a five-to-seven-year hold, and for founders trying to build something that will still matter in 2032, this is an uncomfortable place to be. Why hardware answers the defensibility question Ask a generative model to write a patient-scheduling application and it will do so in an afternoon. Ask it to design, prototype, validate, manufacture, certify, distribute and support a continuous glucose monitor, a surgical robot, a wearable cardiac patch, an implantable neuro-stimulator or a point-of-care diagnostic device, and you will discover the limits of abundance very quickly. Hardware defensibility in HealthTech rests on a stack of moats that compound and almost none of them can be collapsed by better code. Regulatory moats. A medical device that has cleared the FDA through 510(k), De Novo or PMA, or carries UKCA or CE marking under the EU Medical Device Regulation, holds an asset that took years, millions and a great deal of institutional learning to obtain. That clearance is tied to a specific design, a specific manufacturing process and a specific quality management system. A competitor cannot fork it. The very regulatory burden that makes founders groan is the same burden that keeps the field clear once you are through. Physical data moats. The most valuable data in healthcare is not the data that already sits in an EHR; it is the data that has never been captured because no device existed to capture it. Continuous glucose, continuous blood pressure, sweat biomarkers, intracranial pressure, gait, sleep architecture, cardiac rhythm at population scale. The company that owns the sensor owns the only source of that signal, and the AI models trained on it are proprietary in a way that models trained on scraped clinical notes never will be. In an era where software data moats are being eroded, sensor data moats are being created. Manufacturing and supply chain moats. Getting a device from a working prototype to a validated, scalable, cost-effective production line is a discipline in its own right, involving supplier qualification, design for manufacture, tooling, yield optimisation, sterilisation, packaging, cold chain and logistics. It is slow, capital-intensive and full of tacit knowledge. That is exactly why it is defensible. Intellectual property moats. Software patents are notoriously weak and increasingly hard to enforce. Hardware patents, on mechanisms, materials, sensor architectures, form factors and manufacturing processes, remain genuinely enforceable and are routinely the deciding factor in medtech litigation and licensing. Clinical evidence and reimbursement moats. A device backed by randomised trials, real-world evidence, published outcomes, a reimbursement code and inclusion in clinical guidelines is embedded in the practice of medicine. Displacing it requires a competitor to run the same trials and win the same codes, which takes years and cannot be accelerated by a better prompt. Distribution and installed-base moats. Once a device is in the operating theatre, on the ward, in the pharmacy or on the patient's arm, it carries with it consumables, service contracts, training, software subscriptions and a relationship. The razor-and-blade economics of medtech are as old as the industry and they remain one of its most durable features. Put these together and you get something that HealthTech software has struggled to offer investors in the last two years: a credible story about why the company will still be here, and still be growing, when the next model release lands. AI is not the enemy of hardware. It is the accelerant The obvious objection is that AI is coming for hardware too. That is true in one sense and misleading in another. AI is transforming how hardware is designed and built. Generative design, simulation, digital twins, automated firmware development, AI-driven quality inspection and predictive maintenance are compressing hardware development timelines in the same way that code generation has compressed software timelines. The pre-clinical and regulatory phases are being accelerated by AI-assisted documentation and evidence synthesis. Founders who understand this can build hardware companies faster and cheaper than any previous generation, which lowers the barrier to entry without lowering the barrier to defensibility. More importantly, AI needs hardware. The value of a diagnostic model is bounded by the quality of the signal it receives, and the quality of the signal is a hardware problem. The frontier of clinical AI is not better algorithms on the same old inputs; it is new sensors producing new inputs at higher resolution and higher frequency than ever before, and models that learn from them. Continuous multi-analyte wearables, ambient sensing in the home, AI-native imaging and ultrasound, robotic surgery with real-time guidance, brain-computer interfaces, smart implants and closed-loop drug delivery are all AI businesses whose defensibility lives in the physical layer. The term now in common use for this is physical AI, and healthcare is its most obvious and most valuable application. The strategic implication is that the most valuable HealthTech companies of the next decade will be neither pure software nor pure hardware. They will be full-stack: a proprietary device that captures a proprietary signal, a proprietary model that interprets it, and a software and services layer that delivers the result into a clinical workflow and captures recurring revenue. The hardware is the moat. The software is the margin. The AI is the multiplier. Companies that already look like this, in continuous glucose monitoring, surgical robotics and consumer wearables, are precisely the ones that have held their valuations while the software-only cohort has been repriced. What we expect from investors in 2027 We expect 2027 to be the year that the shift from software to hardware in HealthTech becomes visible in the funding data rather than merely in conference-panel conversation. Several forces are converging. The first is the search for defensibility described above. Venture investors are, in the end, in the business of underwriting durability, and the questions in investment committee have changed. Two years ago the question was "how big is the TAM and how fast can you grow?" The question now is "why does this company exist in three years if the model providers decide to do what you do?" Hardware companies have a clear answer; many software companies do not. The second is the return of hard tech as an asset class. The last few years have seen a substantial reallocation of venture capital towards defence, energy, space, robotics, semiconductors and advanced manufacturing, driven by geopolitics, re-shoring, government industrial policy and a generational recognition that atoms matter as much as bits. Funds that built hard-tech competence for those sectors are now looking for adjacent applications, and healthcare, with its enormous markets and clear regulatory pathways, is the natural next stop. Expect more generalist and deep-tech funds to build medtech and health-hardware practices, and expect more crossover between defence, robotics and health-hardware investing than at any time since the 1980s. The third is the maturing of the capital stack for hardware. One of the historical reasons investors avoided hardware was that it needed patient, staged capital and the ecosystem to provide it was thin. That is changing. Venture debt, equipment financing, non-dilutive grant funding, government innovation programmes, strategic corporate venture arms and specialist medtech growth funds have all deepened, and the increasing use of contract manufacturers and outsourced regulatory and quality services has reduced the fixed cost of getting a device to market. Hardware is still capital intensive, but it is less capital intensive relative to software than the folklore suggests, particularly once you account for the cost of customer acquisition in a crowded software market. The fourth is the behaviour of strategic acquirers. The large medtech and diagnostics groups, together with the pharmaceutical companies building device and digital businesses, have consistently paid premium multiples for hardware-enabled companies with clearance, evidence and installed base, and they are increasingly the most active buyers in the lower and mid-market. Software-only HealthTech exits, by contrast, have become harder to underwrite as acquirers ask the same defensibility questions that investors ask. Venture investors follow exit liquidity, and in 2027 exit liquidity in HealthTech will favour companies with something physical to sell. The fifth is simple portfolio construction. Funds that are heavily exposed to application-layer HealthTech software are looking at correlated risk: a single advance in foundation models can impair a dozen portfolio companies at once. Hardware provides diversification against that risk in a way that another software bet cannot. Taken together, we expect to see more first-cheque investors willing to lead hardware seed rounds, more Series A and B capital for companies with early clinical data and a clear regulatory path, more growth capital for scale-ups moving from clearance into commercialisation, and a marked increase in the number of funds that describe themselves, without embarrassment, as investing in "HealthTech hardware" or "physical health AI". What we expect from founders in 2027 The founder side of the shift will be just as significant, and in some ways it is already further along than the investor side. The generation of founders who spent the last decade building HealthTech SaaS has learned two things the hard way. The first is that a beautiful product with a great team can still be commoditised in a single model release. The second is that the customers they spent years learning to sell to, clinicians, hospitals, payers, are more receptive to a device that changes what is physically possible than to another piece of software that changes how something is administered. Many of those founders are now asking what they could build if they let themselves solve a physical problem and increasing numbers are choosing to find out. They are also entering hardware with advantages their predecessors did not have. AI-assisted design and simulation shorten the road to a working prototype. Contract manufacturers and design houses offer medtech-grade development as a service. Regulatory consultants, quality management platforms and outsourced clinical operations lower the fixed cost of compliance. Component ecosystems built for consumer electronics and robotics, sensors, batteries, radios, processors, are cheaper and more capable than ever. And the software half of a full-stack company, the part that was once the whole company, can now be built by a small team quickly, freeing capital and attention for the hardware that actually matters. We expect to see founders concentrating on a handful of high-value themes. Continuous, non-invasive biosensing, in wearables and patches that measure what was previously only measurable by blood draw. Home and ambient care hardware that allows hospitals to move acute and chronic care into the home safely. AI-native imaging and point-of-care diagnostics that bring high-end capability to primary care and low-resource settings. Surgical and interventional robotics, including the next wave of smaller, cheaper, more specialised systems. Neurotechnology and brain-computer interfaces, where the physical layer is inseparable from the clinical value. Smart drug delivery and closed-loop therapeutics. And the unglamorous but enormous category of hardware for the healthcare workforce, from logistics and pharmacy automation to sterilisation and monitoring. The founders who succeed will not be the ones who abandon software. They will be the ones who understand that the software business model, recurring revenue, high margins, data compounding, is best defended when it is anchored to a device that nobody else can make. The playbook is not "hardware instead of software". It is "hardware so that the software is worth something". Nelson Advisors: HealthTech 2027 and the Big Move From Software to Hardware to De-Risk the AI Threat and address the Defendability questions The honest caveats It would be irresponsible to write about a shift to hardware without acknowledging why investors avoided it in the first place. Hardware is hard. Development cycles are longer, capital requirements are lumpier, gross margins are structurally lower, working capital ties up cash, and a manufacturing or supply chain failure can be fatal in a way that a software bug rarely is. Regulatory timelines can slip by years. Reimbursement can take longer still. Product recalls are existential. The failure modes are more numerous and less forgiving, and the skills required, mechanical, electrical, regulatory, clinical, operational, are scarcer than software engineering and harder to assemble in one team. Not every founder should build hardware and not every investor should fund it. Those who do will need to underwrite longer timelines, structure capital in stages that match technical and regulatory milestones, and pay far more attention to unit economics, cost of goods and manufacturing scalability than the software era ever required. They will need boards that understand quality systems and design controls, and they will need to resist the temptation to raise venture capital at software-style valuations against a hardware-style risk profile. There is also a legitimate argument that the correct response to the AI threat is not to flee software but to build better software: AI-native, workflow-deep, embedded in the parts of care where trust, liability and regulation still favour specialist vendors. Some of the best HealthTech companies of 2027 will be exactly that. But the bar has risen, the number of software companies that clear it is smaller than the number that raised money in 2021, and for many teams the honest conclusion is that a physical product offers a better risk-adjusted path to something durable. The M&A lens From where we sit, advising founders and boards on transactions in the lower to mid market, the shift is already visible in the conversations we have. Strategic buyers are prioritising targets that bring them a device, a sensor, a signal or a manufacturing capability they cannot build internally, and they are willing to pay for regulatory clearance, clinical evidence and installed base. They are more sceptical of software-only assets unless those assets are deeply embedded and demonstrably resistant to substitution. Due diligence has changed accordingly: the defensibility section of the process now asks explicitly how the business would be affected by the next generation of foundation models, and hardware-enabled companies have an easier time answering. We expect 2027 to bring more acquisitions of hardware-enabled HealthTech companies by medtech, diagnostics, pharma and, increasingly, by large technology companies building health-hardware ecosystems. We expect more software companies to seek hardware partners or acquisitions of their own to shore up their defensibility and more hardware companies to acquire software and AI teams to complete their stack. We also expect private equity, which has historically preferred the predictable cash flows of healthcare software, to build increasing comfort with hardware-enabled recurring revenue models, particularly where consumables and service contracts provide the annuity that software subscriptions used to. For founders contemplating an exit, the practical implication is that the story the market wants to hear has changed. It is no longer enough to show growth and gross margin. Buyers want to know what you own that cannot be generated, and in 2027 the most convincing answer to that question will increasingly be something you can hold in your hand. Conclusion The software era of HealthTech is not ending, but its unquestioned dominance is. Generative AI has made software abundant, and abundance is the enemy of defensibility. The companies that will command premium valuations, attract the most durable capital and achieve the strongest exits over the next few years will be the ones that anchor their intelligence in the physical world, in devices that capture signals nobody else can capture, that clear regulatory bars nobody else has cleared, and that sit in clinical and consumer settings nobody else can reach. We expect 2027 to be remembered as the year that HealthTech investors and founders stopped treating hardware as the difficult, capital hungry cousin of software and started treating it as the foundation of a defensible business. The moat, it turns out, was never the code. It was the thing the code runs on. Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns.www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA#Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk